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SUMMARY 
Summary 
 
House dust mite (HDM) allergy represents one of the most important allergies 
affecting more than 50% of all allergic patients worldwide and HDMs are associated 
with the development of different allergic diseases such as rhinitis, atopic dermatitis 
and asthma. 
The most effective form of allergy treatment with long lasting effects is allergen 
specific immunotherapy (SIT), which is currently performed with allergen extracts. But 
several studies have revealed the low quality of natural allergen extracts and the 
occurrence of side-effects ranging from mild local to severe and life-threatening 
symptoms, such as anaphylactic shock, during the treatment. A possibility to avoid 
these problems may be the use of hypoallergenic derivatives of the important HDM 
allergens for immunotherapy. 
Among the 24 different groups of mite allergens, group 1 and group 2 allergens 
represent the clinically most important HDM allergens. Therefore, these two proteins 
represent good targets for engineering hypoallergenic allergen derivatives in order to 
 the major T-cell epitopes and hence 
prevent the induction of late-phase side-effects during SIT. When coupled to a 
carrier, the peptides should induce blocking IgG antibodies in animal models (mice 
and rabbits). 
In the second main project, we used the hybrid technology to design mosaic 
molecules containing all primary sequence elements of Der p 1 and Der p 2 in 
improve the safety and efficacy of SIT. The main aim of this thesis was thus the 
production of hypoallergenic derivatives of Der p 1 and Der p 2. 
In the first main project of the thesis, we evaluated a new approach of vaccine 
development, based on the hapten-carrier principle. For this purpose, we synthesized 
five Der p 2-derived peptides, which should lack
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rearranged order in one molecule. The Der p 2/1 mosaic proteins were expressed in 
E. coli and evaluated regarding their allergenic activity, the presence of T cell 
epitopes and their immunogenicity. 
The results showed that the Der p 2 peptides as well as the Der p 2/1 mosaic 
proteins had almost completely lost their IgE reactivity and allergenic activity. 
Whereas the Der p 2/1 mosaic proteins induced similar T-cell proliferation as the 
wildtype allergens, the peptides induced only low T-cell proliferation. Upon 
immunization of mice and rabbits, the Der p 2/1 mosaic proteins as well as the 
carrier-bound Der p 2 peptides induced allergen-specific IgG antibodies. Anti-Der p 
2/1 mosaic antibodies were able to block patients’ IgE binding to both allergens, Der 
p 1 and Der p 2, and a combination of two of the five anti-Der p 2 peptide antibodies 
was sufficient to block patients’ IgE binding to Der p 2 comparable to antibodies 
induced with the wildtype allergen. 
The experiments showed that both hypoallergenic derivatives (Der p 2 peptides and 
Der p 2/1 mosaic proteins) represent good candidates for a safe immunotherapy. 
Whereas the Der p 2/1 mosaic proteins may be used for the treatment of Der p 1 and 
Der p 2 co-sensitized patients and for tolerance induction, the Der p 2 peptides may 
also be used for prophylactic vaccination. 
 
ZUSAMMENFASSUNG 
Zusammenfassung 
 
Einer der wichtigsten Allergien weltweit ist die Hausstaubmilbenallergie, die bei mehr 
als 50% aller Allergiepatienten auftritt. Hausstaubmilben werden oftmals in 
Verbindung gebracht mit der Entwicklung von allergischen Erkrankungen wie 
Rhinitis, atopischer Dermatitis und Asthma.  
Die effektivste Form der Allergiebehandlung mit Langzeitwirkung ist die 
allergenspezifische Immuntherapie (SIT), welche zurzeit mit Allergenextrakten 
durchgeführt wird. Mehrere Studien haben jedoch belegt, dass oftmals die Qualität 
der Extrakte mangelhaft ist. Außerdem können während der Behandlung mit 
Allergenextrakten Nebenwirkungen in Form von leichten lokalen Symptomen bis hin 
zu lebensbedrohlichen Symptomen wie anaphylaktischen Schock auftreten. Eine 
Möglichkeit diese Probleme zu vermeiden wäre die Verwendung von hypoallergenen 
Derivaten von den wichtigsten Hausstaubmilbenallergenen für die Immuntherapie. 
Unter den 24 verschiedenen Gruppen von Milbenallergenen gehören Allergene der 
Gruppe 1 und Gruppe 2 zu den klinisch relevantesten Allergenen. Deshalb sind diese 
zwei Hauptallergene gute Kandidaten für die Herstellung von hypoallergenen 
Derivaten, um die Sicherheit und Effektivität der SIT zu erhöhen. Das Hauptziel 
dieser Dissertation war daher die Herstellung von hypoallergenen Derivaten von Der 
p 1 und Der p 2. 
Im ersten Hauptprojekt dieser Dissertation haben wir einen neuen Ansatz zur 
Impfstoffherstellung evaluiert, welcher auf dem Hapten-Carrier Prinzip basiert. Hierfür 
synthetisierten wir fünf Der p 2 Peptide bei denen die wichtigsten T-Zellepitope 
fehlten, wodurch das Auftreten von T-Zell-vermittelten Nebenwirkungen während der 
SIT verhindert werden soll. Nach der Koppelung an ein Carrier-Molekül, sollten die 
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Der p 2 Peptide schützende IgG Antikörper in unseren Tiermodellen (Mäuse, 
Kaninchen) induzieren. 
Im zweiten Hauptprojekt befassten wir uns mit dem Design von Mosaikproteinen, die 
alle Elemente von Der p 1 und Der p 2 in einem Molekül enthalten. Die Der p 2/1 
Mosaikproteine wurden in E. coli rekombinant hergestellt und auf ihre allergene 
Aktivität, das Vorhandensein von T-Zell Epitopen und auf ihre Immunigenizität 
geprüft. 
Die Resultate zeigten, dass sowohl die Der p 2 Peptide als auch die Der p 2/1 
Mosaikproteine keinerlei IgE Reaktivität und allergene Aktivität aufwiesen. 
Wie die Wildtypallergene waren auch die Der p 2/1 Mosaikproteine in der Lage T-
Zellproliferation zu induzieren, wohingegen die Der p 2 Peptide nur geringe T-
Zellproliferation induzierten. Die Immunisierung von Mäusen und Kaninchen mit den 
Der p 2/1 Mosaikproteinen und Carrier-gekoppelten Der p 2 Peptiden induzierte die 
Bildung von allergen-spezifischen IgG Antikörper. Der p 2/1-spezifischen Antikörper 
waren in der Lage die Bindung von Patienten IgE an Der p 1 und Der p 2 zu 
inhibieren und eine Kombination von nur zwei der fünf anti-Der p 2 Peptid Antikörper 
bewirkte ebenfalls eine Inhibition, die vergleichbar war mit der Inhibition die mit anti-
Der p 2 Antikörper erreicht werden konnte. 
Aus den gewonnenen Erkenntnissen schließen wir, dass beide hypoallergene 
Derivate (Der p 2 Peptide und Der p 2/1 Mosaikproteine) geeignete Kandidaten für 
eine sichere SIT darstellen. Während die Der p 2/1 Mosaikproteine für die 
Behandlung von Der p 1 und Der p 2 allergischen Patienten und für 
Toleranzinduktion verwendet werden können, können die Der p 2 Peptide auch für 
eine prophylaktische Impfung eingesetzt werden. 
 
  
 
 
 
 
 
CHAPTER 1 
 
INTRODUCTION 
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1. Introduction 
 
1.1 History and terminology of allergy 
 
1.1.1 The beginning of Allergology 
One of the first recorded occurrences of an adverse reaction to external agents, 
which were harmless to most people, was reported by the ancient Egypt. There the 
Egyptian pharaoh Menses (2641 B.C.) died due to a wasp sting (the interpretation of 
hieroglyphics is apparently controversial) (1). But it was Dr. John Bostock (1773-
1846) (Figure 1), who described this adverse reaction accurately. In 1819 he 
published a report of his own case, describing hay fever as a disease that affected 
the upper respiratory tract and which commenced around ‘the beginning or middle of 
June in every year. Much later, in 1869, Charles Harrison Blackley (1820-1900) 
(Figure 2) also a hay fever sufferer demonstrated in several experiments carried out 
largely on himself, including the first skin test, that hay fever was caused by pollen 
(2). 
  
Figure 2 Charles H. Blackley first 
Figure 1 John Bostock described for the 
first time hay fever accurately 
performed a skin test (3) 
INTRODUCTION 
The term allergy was first introduced by the Viennese pediatrician Clemens von 
Pirquet (1874-1929) (Figure 3) in 1906, derived from the Greek words ‘allos’ meaning 
‘changed’ and ‘ergos’ meaning ‘action’, describing an ‘altered’ capacity of the body to 
react to a foreign substance (4). Today, allergy is defined as a ‘hypersensitivity 
reaction’ initiated by specific immunologic mechanisms and hypersensitivity is 
defined as objectively reproducible symptoms or signs initiated by exposure to a 
defined stimulus at a dose tolerated by normal persons (5). 
 
 
In 1921, Otto Karl Prausnitz (1876-1963) and Heinz Küstner (1897-1963) (Figure 4) 
performed an important experiment, which improved the understanding of allergy 
significantly. They demonstrated that immediate skin hyper reactivity could be 
transferred by intradermal injection of serum of an allergic individual. Therefore, they 
concluded that allergic reactions depend on two components, a specific component 
present in the serum (reagin) and a non-specific tissue component (7). The 
component ‘reagin’ described by Prausnitz and Küstner remained unknown until 
Kimishige and Teruko Ishizaka in the USA and Hans Bennich and Gunnar 
  
Figure 4 Prausnitz (left) and Küstner (right) described the Figure 3 Clemens von Pirquet coined 
passive transfer of immediate-type skin reactivity by the term 'allergy' (3) 
intradermal injection of serum from an allergic patient (6) 
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Johansson in Sweden independently identified this serum component as 
Immunoglobulin E (IgE) (8-9). 
In 1963, the two British immunologists Robert Royston Amos Coombs and Philip 
Georg Howthern Gell classified hypersensitivity reactions into four different types 
based on the type of pathophysiological mechanisms involved (Figure 5) (10). 
 
 Type I: immediate-type hypersensitivity (IgE mediated hypersensitivity) 
(see below) 
 Type II: antibody mediated, cytotoxic hypersensitivity 
This type of hypersensitivity reaction is mediated by IgG or IgM and 
occurs when these antibodies react with self or foreign tissue-
associated antigens, leading to tissue damage by complement 
activation or by antibody-dependent cellular cytotoxicity (ADCC). Acute 
graft rejection or haemolysis in case of rhesus-incompatibility belongs to 
this type of hypersensitivity. 
 Type III: immune complex-mediated hypersensitivity 
Type III hypersensitivity is triggered by the formation of complexes 
between mainly IgG antibodies or IgM antibodies and soluble antigens. 
 
Figure 5 The four types of hypersensitivity reactions according to Coombs and Gell (11) 
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The deposition of these complexes in the tissue leads to activation of 
complement as well as macrophage and neutrophils causing tissue 
destruction.  
 Type IV: delayed-type / cell-mediated hypersensitivity 
Antigen is presented to CD 4+ and CD 8+ T lymphocytes, which leads 
to the infiltration of these activated cells causing inflammation by the 
release of proinflammatory cytokines. This type of reaction takes more 
than 12 hours and up to 3 days to develop. 
 
1.1.2 Type I Hypersensitivity – Allergy (immediate type hypersensitivity) 
Type I allergy is mediated by IgE antibodies and is the most common type of 
hypersensitivity affecting more than 25% of the population worldwide with increasing 
prevalence (12-13). 
Allergic reactions are initiated by the cross-linking of effector cell-bound IgE, caused 
by the contact with allergens, which leads to the release of vasoactive and 
inflammatory mediators (e.g. histamine, leukotrienes). These mediators cause within 
minutes the characteristic allergic symptoms such as allergic rhinitis, conjunctivitis, 
urticaria, dermatitis, diarrhea, bronchial asthma and as most severe and life-
threatening symptom, anaphylactic shock. 
The development of allergy may be explained by atopy. This term was introduced in 
1923 by Coca and Cooke describing a strange, abnormal type of hypersensitivity 
against environmental substances, which was observed only in humans and tended 
to occur within families without obvious prior sensitization (14). Today atopy is 
defined as a personal and /or familial tendency to become sensitized and produce 
IgE antibodies in response to ordinary exposures to allergens and these persons can 
develop typical symptoms of allergy like asthma, rhinoconjunctivitis, or eczema (5). 
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But genetic factors alone cannot explain the development and the rising prevalence 
of allergic diseases. Therefore David P. Strachan introduced the hygiene hypothesis 
in 1989, which further explain the development and the increasing prevalence 
including the environmental factors (15). The hygiene hypothesis states that the 
immunsystem at birth is immature and tends to induce T helper 2 (TH2) cell 
associated cytokines. Certain stimuli, such as infections with viruses, microbes, 
helminthes or other environmental factors, can direct the immune system towards a 
healthy balance of TH1 and TH2 cell associated cytokine responses. In the absence 
of these stimuli, when children living in a relatively sterile environment, the immature 
TH2 cell associated cytokine production persists and leads to an increased risk of 
allergy (Figure 6) (16-19).  
 
 
Figure 6 The hygiene hypothesis. According to this hypothesis, 
certain environmental stimuli, such as different infections (from 
siblings or peers in day care centres) in early childhood, will direct 
the immune system towards a healthy balance of TH1 and TH2 
responses. The absence of these stimuli (‘sterile’ urban 
environments), will lead to an increased risk of allergy (17). 
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1.1.3 Allergen 
Allergens are defined as antigens stimulating hypersensitivity mediated by an 
immunologic mechanism (20). Allergens are mostly proteins or glycoproteins, in 
certain circumstances pure carbohydrates, with molecular masses of 5-80 kDa 
without common structural or biological features deriving from pollen, mites, animal 
dander or foods (21-23). When an allergen is recognized by more than 50% of 
allergic patients then this allergen is designated as major allergen. IgE antibodies are 
able to recognize an allergen by the 
(conformational epitope). 
 
1.2 Mechanisms of Type I allergy 
 
The course of allergy can be distinguished into three phases (Figure 7): 
1. Sensitization and memory 
2. Immediate phase reaction 
3. Late phase reaction 
 
 
sequence (linear epitope) or structure 
 
INTRODUCTION 
 
Figure 7 (a) Sensitization induced by allergen contact with antigen-presenting cells, followed by IgE 
production and formation of specific B cell and T cell memory. (b) Immediate phase (type 1 reaction) 
initiated by allergen-induced cross-linking of basophil- and mast cell-bound IgE. (c) Late phase 
 
The first contact with an allergen and the following immune response is known as 
sensitization, which often occurs in early childhood (25-27). The mucosa seems to 
play an important role for the uptake of the allergens (28-29). In case of inhalant 
allergens (e.g. allergens form pollen, dust mite), minute amounts of the allergens are 
released on the mucosal surface of the respiratory tract and are then taken up by 
present antigen presenting cells (APC) (e.g., dentritic cells, macrophages) and/or 
captured by the surface bound immunoglobulin of a B cell. These APCs activate 
naïve T cells by the presentation of allergen peptides on MHC molecules to the T cell 
receptor (TCR) in the lymph nodes. Allergen presentation results in the differentiation 
of naïve T cells into allergen specific TH2 cells, which preferentially produce cytokines 
such as interleukin-4 (IL-4) and IL-13 (30). These two cytokines promote the 
immunoglobulin class switch of B cells to IgE (31). The sensitization process leads to 
the establishment of allergen specific long-lived memory T cells that respond to 
repeated allergen contact (32) and allergen-specific IgE+ memory B cells (27). 
(allergic inflammation) mediated by allergen-specific T cells (24). 
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Repeated allergen contact also leads to an increased IgE production by IgE+ memory 
B cells (33). 
The immediate phase of the allergic reaction is characterized by the immediate 
occurrence of allergic symptoms after allergen contact. This reaction is mediated by 
IgE antibodies, which bind to the surface of mast cells and basophils via the IgE high 
affinity receptor, FcεRI (34). Allergen-induced crosslinking of FcεRI-bound IgE on the 
effector cells leads to the release of inflammatory mediators (e.g., histamine, 
leukotrienes), which causes the typical allergic symptoms, such as rhinitis, 
conjunctivitis and asthma within minutes. 
Late phase reactions occur in allergic individuals, who suffer from chronic 
manifestations of atopy (e.g., chronic asthma, atopic dermatitis) and the symptoms 
appear four to twelve hours after allergen exposure. They are mainly caused by the 
activation and proliferation of allergen specific TH2 cells via allergen presentation, 
which leads to the release of proinflammatory cytokines (e.g., IL-4, IL-5, IL-13) (35). 
The release of IL-5 induces the accumulation of eosinophils (36). TH1 cells may also 
be involved in late phase reactions by releasing INFγ and TNF. 
 
1.3 Mite Allergy 
 
1.3.1 History of house dust mite allergy 
In 1922, Robert A. Cooke first published the observation that house dust represents 
an omnipresent allergen source (37). There he reported in a case study about an 
asthmatic patient who had severe symptoms when he was at home but the 
symptoms disappeared spontaneously when he was away from home and recurred 
when he was back home. At that time, house dust could be identified as the cause of 
the symptoms by using house dust extracts in skin prick tests but the allergen source 
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remained unknown (38). In the years 1924 to 1930, Willem Storm van Leeuwen and 
his coworkers speculated that mites could be involved in the origin of the house dust 
allergen. But they were not able to prove the relationship between mites and the 
allergenic properties of house dust (39). Also Dekker suggested in 1928 that mites 
played an important role in house dust but his evidence was unconvincing (40-41). In 
the early 1960s, Voorhorst was very interested in the origin of house dust allergen 
and therefore he began to study different possible biologic sources of the house dust 
allergen, such as fungi, animal skin scales, insects and also mites. He also 
performed skin test studies with extracts of storage mites and was then convinced 
that storage mites were not the origin of house dust allergens (39). The breakthrough 
came in the mid-1960s, with the help of the biologist Boezemann, Voorhorst and 
colleagues discovered a rather unknown mite species in house dust, which was 
classified as Dermatophagoides species (42). The number of this unknown mite 
species strongly correlated with the allergenicity of house dust. With the successful 
cultivation of Dermatophagoides pteronyssinus (43), Voorhorst and Spieksma were 
able to prove that this mite species was the producer of the house dust allergen and 
they published their first fully documented manuscript in June 1967 (44). And soon 
confirmative reports were published by other groups (45-47). 
At the same time, a Japanese biologist, Oshima reported independently from 
Voorhorst and his coworkers the finding of Dermatophagoides species in “tatami” 
floor coverings (48). Miyamoto and his coworkers identified this mite species as 
Dermatophagoides farinae and considered these mites as the causative agent in 
bronchial asthma (49). This was the first confirming report from outside Europe. 
Later, in 1970, Wharton suggested calling D. farinae “the North American house dust 
mite” and D. pteronyssinus “the European house dust mite” (Figure 8) (50). 
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1.3.2 Taxonomy and prevalence of mites 
House dust mites are arthropods belonging to the subphylum Chelicerata, class 
Arachnida, order Acari, and suborder Astigmata (Figure 9). The genus 
Dermatophagoides was first named and described by Bogdanov in 1864 (52). 
Figure 8 House dust mites. (left) Dermatophagoides pternonyssinus, (right) Dermatophagoides farinae (51). 
 
Figure 9 A taxonomic scheme of some common domestic mites 
 
Around 50,000 species of mites are known but only 13 species can be found in 
house dust located throughout the world (53). Out of these 13 species, three species, 
Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Euroglyphus 
maynei are most common comprising up to 90% of the house dust mite fauna and 
are the major source of mite allergens (54-56). D pteronyssinus is distributed from 
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temperate to tropical regions and E maynei is also found in temperate regions but in 
lower abundance, whereas D farinae is found in drier regions (57-58). In tropical and 
subtropical regions, the storage mite Blomia tropicalis can be a dominant part of 
house dust and the dominant allergen source (59). 
Beside the house dust mites, other mites especially the storage mites Glycyphagus 
domesticus, Lepidoglyphus destructor, Tyrophagus putrenscentiae and Acarus siro 
can be present in homes and are potent allergen sources (60-62). 
In general, the most prevalent mites which can be found in homes are D. farinae and 
D. pteronyssinus and most houses are co-inhabited by both of them (63-64). Usually 
one species dominates in each home and comprises more than 70% of the total mite 
population. Within the same geographic area, the predominant mite species can vary 
between homes (64). 
 
1.3.3 Life cycle 
The life cycle of D. farinae, D. pteronyssinus, and E. maynei consists of 5 stages: 
Egg, larva, protonymph, tritonymph, and adult. Mites are poikilothermic (they cannot 
control their body temperature) and therefore the duration of development from egg 
to adult and population growth is influenced by temperature and also by the relative 
humidity. For the great majority of domestic mites, temperatures of 20-30°C are 
optimal and the optimal values of relative air humidity lie between 70 and 90%. The 
adults live for about 4–6 weeks, during which time each female produces 40-80 eggs 
(65-66). 
 
1.3.4 Sensitization to mites 
About 10 % of the population and more than 50% of all allergic patients are 
sensitized to house dust mites (12, 67). In Europe, most people are sensitized to D. 
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pteronyssinus due to the high prevalence of this mite species (68), but sensitizations 
to D. farinae and E. maynei are also very common (69-71). Co-sensitization to 
storage mites frequently occurs in individuals sensitized to Dermatophagoides spp. 
Depending on the region, 28% to 88% of house dust mite allergic patients are 
sensitized to storage mites (72-76). The IgE reactivity to several mite species might 
be due to the co-existence of house dust mites and storage mites resulting in co-
sensitizations, but may also be the consequence of the existence of several cross-
reacting allergens. However, only limited cross-reactivity has been found between 
house dust and storage mites (77). 
 
1.3.5 Mite allergens 
Mite allergens are divided into specific groups according to their biochemical 
composition and sequence homology. More than 30 proteins in house dust mite 
extracts show IgE reactivity with sera of mite allergic patients (78-79). According to 
the allergen database (Allergome, www.allergome.org), 24 groups of mite allergens 
have been identified (Table 1). Almost all of these 24 mite allergens were produced 
as recombinant proteins, which are useful for the analysis of the molecular structure, 
immunological properties of the allergens and for diagnosis and therapy of mite 
allergy (80-83). 
The most important groups of mite allergens are the group 1 and group 2 allergens, 
which are characterized by high IgE reactivity and allergenic activity. The group 1 
and group 2 allergens such as Der p 1 and Der p 2 from D. pteronyssinus can block 
50% of the IgE binding to house dust mite extracts (84-85). 
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Table 1 (modified from (80)) 
MW cDNA1 (SDS-PAGE) Species2 IgE binding3 Group Biochemical function 
1 Cysteine protease 25,000 Dp, Df, Dm, Ds Em 80–100 
2 Unknown (HE1 homologue) 14,000 Dp, Df, Ds, Em, Ld, Tp, Gd, As 80–100 
3 Trypsin 25,000 (30,000) Dp, Df, Ds, Em 16–100 
4 α-Amylase 57,000 Dp, Em 40–46 
5 Unknown 15,000 Dp, Bt, Ld 21-57 
6 Chymotrypsin 25,000 Dp, Df 40 
7 Unknown 25,000 (31,000, 29,000, 
26,000) 
Dp, Df, Ld 50 
8 Glutathione-S-transferase 26,000 Dp 40 
9 Collagenolytic serine protease no cDNA, (30 000) Dp 90 
10 Tropomyosin 37,000 Dp, Df 0–32 
11 Paramyosin 96,000 (92,000, 98,000) Df, Bt 80 
12 Unknown 14,000 Bt 50 
13 Fatty acid-binding protein 15,000 Bt, Ld, As 10–23 
14 Vitellogenin/apolipophorin-like 177,000 (variable) Df, Dp, Em 90 
15 98,000 Chitinase 62,500 (98,000, 105,000) Df 70 
16 Gelsolin 55 Df 35 
17 Ca-binding EF protein 30 Df 35 
18 Chitinase 60,000 Df 60 
19 Anti-microbial peptide 7,000 Bt 10 
20 Arginine kinase 40,447 Df, Dp, Bt, Gd, 7-44 
21 Unknown 14,000 Df, Dp, Bt 26 
22 Unknown 16.900 Df Unknown 
23 Unknown 14,000 Dp Unknown 
24 Troponin C 17,700 Tp Unknown 
1 MW calculated from cDNA (SDS-PAGE of natural allergen, if different). 
2 Allergen described for the species designated by initials: Dermatophagoides pteronyssinus, Dermatophagoides farinae, 
Euroglyphus maynei, Dermatophagoides siboney, Dermatophagoides microceaus, Lepidoglyphus destructor, Blomia tropicalis, 
Tyrophagus putrescentiae, Glycophagus domesticus, Ascaris siro. 
3 Binding frequency (% patients, variation due to different studies). 
 
Group 1 Allergens 
The first described major mite allergen was the group 1 allergen from D. 
pteronyssinus, Der p 1 in 1980, against which more than 80% of all mite-allergic 
patients are sensitized (84, 86). The cDNA coding for Der p 1 was isolated in 1988 
(87). Der p 1 represents a papain-like glycosylated cysteine protease with 222 or 223 
aminoacid residues and a calculated MW of 25,000 Da (88-89), which originates from 
cells lining the intestinal tract of mites (90) and is present in mite faeces in high 
concentrations (68, 91). Structural analysis showed that Der p 1 consists of two 
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globular domains connected by a flexible linker and the protein is dominated by α-
helices (92). The comparison of Der p 1 and Der f 1 showed a sequence homology of 
81% (93) and the sequence of Eur m 1 (94) from Euroglyphus maynei also showed 
80% homology to both Der p 1 and Der f 1 (80). 
Some studies reported that Der p 1 has mixed cysteine and serine protease activity 
(95-96), but recent studies showed that this serine protease activity does not 
originate from Der p 1 (89). The cysteine protease activity seems to enhance the 
pathogenesis of the allergen. First, Der p 1 is able to cleave the tight junction 
adhesion protein occludin, which causes then the disruption of the epithelial 
paracellular permeability barrier (97-98). This mechanism would facilitate the allergen 
uptake. Second, Der p 1 is capable of cleaving human proteins with potentially 
immunomodulatory effects including α1-proteinase inhibitor (A1-Pi), CD23 (human 
low affinity IgE receptor), and CD25 (α subunit of the IL-2 receptor on T cells). A1-Pi 
protects the lower respiratory tract against damage by proteinases released during 
inflammation and the cleavage of this protein by Der p 1 can promote airway 
inflammation and asthma (99). CD23, the low affinity IgE receptor can be found on B 
cells, eosinophils, dendritic cells and macrophages. Membrane CD23 on B cells and 
its soluble fragments are involved in the regulation of IgE synthesis (100-101). The 
cleavage of this membrane CD23 by Der p 1 may then enhance the IgE synthesis 
(102-103). As a result of the cleavage of CD25, the α subunit of the IL-2 receptor on 
T cells, these cells show a markedly reduced proliferation and interferon-γ (IFN-γ) 
secretion and shift the development of TH-cell subsets in favour of TH2 (104-105). 
Another study showed that Der p 1 is able to degrade and inactivate lung surfactant 
proteins A and D, which seem to play a protective role in allergy (106). 
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Group 2 Allergens 
First, group 2 allergens were described as 14,000-18,000 Da protein with high IgE-
binding capacity (85, 107). After isolating the cDNA coding for Der p 2, analysis of 
this protein showed an allergen with 129 amino acid residues and a molecular weight 
of 14,000 Da without N-glycosylation sites (108-109). The Der p 2 allergen was 
localized in the digestive tract and in the faecal pellets of mites (110). NMR and X-ray 
crystallography indicated that Der p 2 consists of two anti-parallel three-stranded β-
sheets (111-112). Comparison of Der p 2 and Der f 2 showed a sequence homology 
of 88% and Eur m 2 has 82% sequence homology to both Der p 2 and Der f 2 (80). 
The biological function of group 2 allergens is still unknown but sequence analysis 
has revealed that group 2 allergens exhibit sequence homology with MD-2 related 
lipid recognition (ML) domain protein families (113-114). Further, structure analysis of 
Der p 2 showed structural homology with the MD-2 protein, a lipopolysaccharide 
(LPS)-binding component of the Toll-like receptor (TLR) 4 signalling complex (115). 
But Der p 2 not only show structural homology with MD-2, it also mimics the function 
of MD-2, by presenting LPS to the Toll-like receptor-4 for the activation of 
inflammatory genes and this mimicry may enhance the allergenicity of Der p 2 (116-
117). 
 
1.4 Immunotherapy 
 
The easiest way of allergy treatment is to avoid the allergen contact but in many 
cases this is very difficult to achieve, especially in case of airborne allergies like 
pollen or house dust mite allergy. An alternative to allergen avoidance and a widely 
used form of allergy treatment is pharmacotherapy. These drugs have the ability to 
prevent the degranulation of mast cells, neutralize certain mast cell mediators, 
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suppress T cell activation, exhibit general anti-inflammatory activity or reverse 
bronchioconstriction or vasodilatation. An example for drugs neutralizing certain mast 
cell mediators are antihistamines, which were discovered by Daniel Bovet in the 
1930’s (118-119). Beside antihistamines, corticosteroids, drugs with anti-
inflammatory activity, are also widely used to treat allergy and were discovered by 
Edward Kendall and Philip Hench (120). The advantages of pharmacotherapy are the 
immediate effect of the drugs, the low cost and the easy administration. But 
symptomatic medication fails to target the mechanisms underlying allergic diseases, 
often has short activity, may exhibit several side-effects, and is sometimes only 
effective when administered in combination with other drugs (121). 
 
1.4.1 Immunological mechanisms of SIT 
At present, allergen-specific immunotherapy (SIT) is the only causative and disease-
modifying treatment of allergy with long lasting effects (24, 122-125) and is based on 
the repeated administration of increasing doses of the disease-eliciting allergen 
extracts. SIT with natural allergen extracts was introduced by Leonard Noon in 1911 
(126) and has since then been practiced in a similar manner. The efficiency of SIT 
has been demonstrated in numerous clinical trials (127-128) and it seems that 
several immunological mechanisms are involved in specific immunotherapy (Figure 
10). It has been shown that SIT modifies the responses of several immune cells 
towards allergens, like antigen presenting cells (APCs), T cells, B cells and effector 
cells. During SIT, allergen specific IgG antibodies are induced, which are able to 
compete with IgE for allergen binding. These IgG antibodies block patients’ IgE 
binding to the allergen and thereby prevent an allergen-induced activation of effector 
cells as well as an IgE-mediated presentation of allergens to T cells (129-132). 
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Further, the boosting of allergen-specific IgE antibody production by allergen 
exposure can be reduced by SIT-induced blocking IgG antibodies (133-135). 
Beside the induction of blocking IgG antibodies, SIT influences also many other 
different immune mechanisms as the activation of regulatory T cells, the increase of 
the ratio of TH1 to TH2 cytokines and the increase of cytokine production with 
regulatory activity as IL-10 or TGF-β (136). 
 
1.4.2 Modifications and new concepts for SIT 
Performing SIT with natural allergen extracts has several disadvantages, which limit 
the broad application, like the possible induction of severe anaphylactic side-effects. 
Further, the poor quality of the extracts may be the reason for unsuccessful SIT (137-
139) and especially in certain clinical manifestations of allergy such as asthma and 
atopic dermatitis and for certain allergen sources such as house dust mite, moulds 
cat, dog and food, the poor quality of allergen extracts is a major limiting factor for 
 
Figure 10 Overview of the mechanisms in allergen-specific immunotherapy (SIT). SIT has influence on 
different immune cells. During SIT the ratio of TH1 cytokines to TH2 cytokines is increased, IL-10 and TGF 
β production is increased and B cells produce blocking IgG1 and IgG4. All the mechanisms are associated 
with the improvement of quality of life (24). 
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successful SIT (140-141). Furthermore, new IgE reactivities to allergens against 
which the patient was not sensitized before the treatment might be induced during 
SIT with allergen extracts (142). 
Since the introduction of SIT by Noon in 1911, many efforts have been made to 
reduce the side effects of specific immunotherapy. The first important improvement of 
SIT in the 1930s was the use of adjuvants (e.g. aluminum hydroxide), which had the 
aim to keep allergens at the injection site and therefore reduced the risk of systemic 
side-effects (143). Further, adjuvants should increase the immunogenicity of the 
allergy vaccine and therefore induce higher levels of allergen specific IgG antibodies 
than aqueous extracts. Meanwhile, novel adjuvants have been introduced (e.g. 
monophosphoryl lipid A), which may induce stronger humoral and cellular immune 
responses than aluminum hydroxide and may favour TH1 immune responses (133, 
144-145). After the introduction of adjuvants, many research groups started to modify 
the allergen extracts chemically – so called “allergoids”, in order to reduce IgE-
mediated side effects (146-151). 
Many research groups also put some effort into the development of other routes of 
administration beside the traditional subcutaneous application. The reasons were to 
ease the application of SIT (i.e. non-injective), which enables the self-administration, 
and the improvement of patient compliance. The alternative routes of immunotherapy 
included local nasal (LNIT), local bronchial (LBIT), oral (OIT) and sublingual (SLIT) 
(152). The only alternative route of immunotherapy, which has been used in clinics, is 
SLIT (153-154). 
With the introduction of molecular biological techniques into the field of allergy 
research in the 1990s, an increasing number of recombinant allergens has become 
available, which can substitute the natural allergens (155). Recombinant allergens 
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allowed the development of new strategies for allergy diagnosis and immunotherapy 
(Figure 11) (156-158). 
 
One of the new strategies for SIT was the induction of tolerance by allergen-derived 
T cell epitope-containing peptides (160-161). These peptides are too small to be 
recognized by IgE antibodies and should hence not induce IgE mediated side effects 
during SIT but should induce immune tolerance against the allergen. Several clinical 
trials showed that the peptides did not induce IgE-mediated side-effects (162-164), 
however, late phase reactions occurred due to the MHC-dependent activation of 
allergen-specific T cells (165-167). 
 
 
Figure 11 Different strategies for immunotherapy. With the availability of cDNAs from 
different allergens and the technique to produce recombinant allergen various allergy 
vaccines can be engineered based on different strategies such as wild-type-like 
recombinant allergens, hybrid molecules, hypoallergenic derivatives, T cell and B cell 
peptides as well as DNA vaccines (159).  
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Another new approach was the use of recombinant allergens for SIT and a clinical 
study with the recombinant birch pollen allergen Bet v 1 showed several advantages 
compared to vaccines based on birch pollen extracts (168). Recombinant allergens 
were further modified into recombinant hypoallergenic allergen derivatives with the 
aim to reduce their IgE binding capacity. Hypoallergenic derivatives were produced 
by introducing point mutations, by deletion of parts of the sequences, by 
fragmentation, by oligomerization, and by fusion of allergen variants (123, 159). 
Recombinant hypoallergenic derivatives are characterized by reduced IgE reactivity 
and allergenic activity but retained immunogenicity and T cell reactivity. 
Immunotherapy studies with recombinant hypoallergenic derivatives of the birch 
pollen allergen Bet v 1 showed promising results (134, 169-170). Another advantage 
of this approach is the possibility to design one hypoallergenic hybrid molecule 
containing several clinically relevant allergens. This development is important for 
allergen sources with more than one major allergen (e.g. grass pollen allergy, house 
dust mite allergy, …) (171). An additional advantage of these hypoallergenic hybrid 
molecules is the increased immunogenicity of low immunogenic allergens by fusion 
with other allergens (172-173). But recombinant hypoallergenic allergen derivatives 
normally contain allergen specific T cell epitopes, which may induce T cell mediated 
side effects. 
To address the problem of T cell mediated side effects, a new approach has been 
developed recently, based on the hapten-carrier principle, discovered by Baruj 
Benacerraf and his co-workers (174-175). In this approach, allergen derived 
peptides, containing no or minimal T cell epitopes, are coupled to a carrier molecule. 
These peptides should show reduced IgE reactivity and due to the lack of T cell 
epitopes they should not activate allergen specific T cells. The carrier-conjugated 
peptides should activate a carrier-specific T cell response upon immunization and 
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therefore enable the induction of anti-peptide IgG antibodies, which should block the 
binding between patients’ IgE and the allergen. A suitable and well-established 
carrier would be keyhole limpet haemocyanin (KLH), a protein from the giant sea 
mollusc Megathura crenulata, which has already been used for vaccination in 
humans (176-177). The approach with carrier conjugated peptides has been 
evaluated for birch and grass pollen allergy with promising results to generate an 
allergy vaccine without IgE and T cell mediated side effects (178-179). 
 
1.5 Aims of the thesis 
 
Type I allergy affects about 25% of the population in Western countries with rising 
prevalence. House dust mite (HDM) allergy represents one of the most important 
allergies affecting more than 50% of all allergic patients worldwide and HDMs are 
associated with the development of different allergic diseases such as rhinitis, atopic 
dermatitis and asthma. 
For allergy treatment and prevention of progression into allergic asthma, specific 
immunotherapy (SIT) represents the most effective form of treatment, which is based 
on the administration of increasing doses of the disease-eliciting allergen extracts. 
Immunotherapy studies with HDM extracts demonstrated their efficacy but allergen 
extracts have major disadvantages, like the heterogeneous amount of allergens in 
allergen extracts, the possibility to induce anaphylactic shock during SIT and the 
possible induction of IgE-responses to new allergens. 
The main aim of the thesis was to produce hypoallergenic derivatives of Der p 1 and 
Der p 2, the most important allergens of HDMs, to improve the efficacy and safety of 
SIT against HDM allergy. 
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Therefore in Chapter 2, we evaluated a new approach of vaccine development, 
which is based on the hapten-carrier principle. For this purpose, we have synthesized 
five Der p 2-derived peptides and evaluated them concerning vaccine safety and 
efficacy. An important aspect of this project was to determine whether these peptides 
are hypoallergenic and show reduced T cell reactivity. Furthermore, we tested if the 
peptides are able to induce blocking IgG antibodies in animal models (mice and 
rabbits), when conjugated to a carrier. The induction of blocking antibodies is 
essential for a successful SIT. With this new strategy, it may be possible to avoid B 
cell- and T cell-mediated side-effects during SIT and the new vaccine may also be 
used for prophylactic vaccination. 
In Chapter 3, we used the hybrid technology to design mosaic molecules containing 
all primary sequence elements of Der p 1 and Der p 2 in rearranged order in one 
molecule for the treatment of Der p 1 and Der p 2 sensitized patients. We produced 
two recombinant mosaic proteins, designated Der p 2/1C and Der p 2/1S. Der p 2/1C 
contained the original aminoacid sequences of Der p 1 and Der p 2, whereas in Der p 
2/1S the cysteine-residues were replaced by serine-residues. We evaluated the 
mosaic proteins regarding their allergenic activity, the presence of T cell epitopes and 
their immunogenicity. The mosaics should induce protective IgG responses to Der p 
1 and Der p 2 and should contain T cell epitopes for vaccination approach and 
tolerance induction. 
SIT was proven to be effective in patients with allergic rhinitis and mild asthma but 
only few studies were done in atopic dermatitis patients with controversial results. In 
Chapter 4, the clinical improvement and the immunological changes were studied in 
HDM-allergic patients with atopic dermatitis undergoing SIT with HDM allergoid. 
My contribution to this project was to provide the allergen Der p 2 by expressing it in 
E. coli and purifying it via affinity chromatography. Furthermore, I evaluated the 
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kinetics of IgG and IgE responses to HDM allergens of patients undergoing SIT in 
ELISA assays. 
Chapter 5 deals with the question, whether the exposure to a farming environment 
has allergen-specific protective effects on TH2-dependent isotype switching in 
response to common inhalants. The reactivity of serum IgG and IgE from children 
who were living on a farm or were exposed to stable/farm milk in the first year of life 
to grass pollen, cat and mite was evaluated by ELISA. 
In Chapter 6, the impact of cigarette smoke exposure on allergy was investigated. 
This study investigated whether cigarette smoke can directly impair the barrier 
function of the respiratory epithelium for inhalant allergen such as birch, grass or mite 
allergens. 
In Chapter 7 it was investigated whether the surface enzyme aminopeptidase N 
(CD13) can be used as a novel marker for allergen-induced activation of basophils in 
allergic individuals. 
My contribution to Chapter 5, 6 and 7 was to provide the major mite allergen Der p 2 
for these projects. 
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Abstract 
Background: More than 90% of HDM-allergic patients are sensitized to one of the most 
important respiratory allergens, the major Dermatophagoides pteronyssinus allergen, Der p 2. 
The aim of this study was to construct a novel type of allergy vaccine, which lacks IgE- as 
well as T cell-mediated side effects by using minimal structural elements of Der p 2. 
Methods: Five Der p 2 peptides (P1-P5) were synthesized and analyzed regarding IgE 
reactivity and allergenic activity. Lymphoproliferative and cytokine responses induced with 
Der p 2 and Der p 2 peptides were determined in PBMCs from mite allergic patients. Der p 2-
specific IgG antibodies induced with carrier-bound Der p 2 peptides in mice and rabbits were 
tested for their capacity to inhibit IgE binding and basophil activation. 
Results: Out of 5 overlapping peptides (P1-P5) covering the Der p 2 sequence, we identified 
two peptides (P2, P4) which lacked IgE-reactivity, allergenic activity and did not induce 
relevant Der p 2-specific T cell proliferation or release of pro-inflammatory cytokines. 
Carrier-coupled P2 and P4 induced Der p 2-specific IgG antibodies in animals, which 
inhibited allergic patients’ IgE binding to the allergen and allergen-induced basophil 
activation to a similar extent as IgG antibodies induced with complete Der p 2. The peptides 
were modelled onto the three-dimensional structure of Der p 2 and found to define a major 
IgE-epitope containing area on one side of the allergen. 
Conclusions: This novel type of peptide vaccine should be suitable for therapeutic and 
prophylactic allergy vaccination. 
 50 
CHAPTER 2 
Key words 
Der p 2, House dust mite allergy, immunotherapy, peptides 
 
Abbreviations used 
SIT: specific immunotherapy 
HDM: house dust mite 
KLH: keyhole limpet haemocyanin 
PBMC: peripheral blood mononuclear cell 
SI: stimulation index 
RBL: rat basophil leukemia cells 
 
Word count: 4119
 51
CHAPTER 2 
INTRODUCTION 
The Dermatophagoides pteronyssinus allergen, Der p 2 is one of the most potent and frequent 
HDM allergens, which is recognized by more than 90% of HDM-allergic patients (1). It 
represents a 15 kDa ß-sheet protein which exhibits extensive sequence and structural 
similarity with group 2 allergens from other mites species (2). Furthermore, it cross-reacts 
with group 2 allergens from other dust mite species at the IgE antibody and at the T cell level 
(1). 
Several approaches have been taken to engineer recombinant hypoallergenic derivatives of 
group 2 mite allergens for improving the safety of house dust mite SIT. With the aim to 
disrupt the conformational IgE epitopes of group 2 allergens, recombinant mutants and 
deletion variants have been produced (3-8). Furthermore, hypoallergenic fragments and 
hybrids of Der p 2 have been engineered (9). These hypoallergenic derivatives exhibit 
reduced IgE reactivity and allergenic activity but the allergen-specific T cell epitopes have 
been preserved in these constructs. This may represent a possible disadvantage because it has 
been shown in clinical studies performed with recombinant hypoallergens and T-cell-reactive 
peptides that IgE-mediated side effects can be abolished but T cell-mediated side effects still 
occur (10-13). 
Here we present a strategy for generating a Der p 2-based vaccine which should eliminate 
IgE- and T cell-mediated side effects. Using synthetic peptide chemistry we prepared five Der 
p 2-derived peptides which lack IgE reactivity and IgE-mediated allergenic activity. Using 
cultured PBMCs from HDM-allergic patients, peptides were identified which induced lower T 
cell proliferation and pro-inflammatory cytokine release than Der p 2. Among these peptides, 
two were identified which, when coupled to a carrier molecule, induced allergen-specific IgG 
antibodies upon immunization. These peptides induced allergen-specific IgG antibodies, 
which were able to block allergic patients IgE recognition and allergen-induced basophil 
degranulation equally well as antibodies against complete Der p 2.
 52 
CHAPTER 2 
METHODS 
Sera from allergic patients, rDer p 2 and hypoallergenic Der p 2 derivatives 
HDM-allergic patients (n=45) were selected according to case history, skin prick testing and 
serological analysis as described (14). Sera from non-allergic individuals were included for 
control purposes. rDer p 2 and recombinant hypoallergenic Der p 2 derivatives (rDerp 2 
fragments: aa 1-53; aa 54-129 and hybrid aa 54-129+1-53) were expressed in E.coli strain 
BL21 (DE3) (Novagen Inc.) and purified as described (9). Purified rDer p 2 was subjected 
another affinity chromatography step using immobilized polymyxin (Affi-Prep Polymyxin 
Matrix, Bio-Rad, Hercules, CA, USA) to reduce endotoxin contents. The endotoxin contents 
in the rDer p 2 preparations were determined with the Limulus-Amebocyte-Lysate assay 
(BioWhittaker, Walkersville, MD, USA) and were typically in the range of 25-110 EU ml-1 
(endotoxin Unit). 
 
Chemical synthesis and characterization of Der p 2 peptides 
Five overlapping peptides spanning the Der p 2 sequence (Fig. 1A) with a length of about 30 
amino acids were synthesized using a Fmoc (9-fluorenylmethoxycarbonyl) strategy with 2-
(1H-Benzotriazol-1-yl) 1,1,3,3, tetramethyluronium hexafluorophosphat (HBTU)-activation 
(15). The peptides were purified by preparative HPLC and their identities were confirmed by 
mass spectrometry.  
The solvent-accessible surface (SAS) of each amino acid residue was calculated with the 
program MSMS (16), which is determined by a spheric solvent probe (r = 1.4Å) rolling over 
the van der Waals surface of the protein and is displayed in Å2. The surface exposure of the 
peptides was calculated as follows: Surface exposure [%] = SAS of all aminoacids of the 
peptide / SAS of all aminoacids of the protein * 100. 
 
IgE reactivity of dot-blotted rDer p 2 and Der p 2 peptides 
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0.2 g of purified rDer p 2, Der p 2 peptides (Peptide 1-5) and, for control purposes, BSA 
were dotted onto nitrocellulose (Schleicher & Schuell, Dassel, Germany) and IgE reactivity 
was determined by using sera from 28 HDM-allergic patients as described (9). 
 
T cell proliferation assays and cytokine measurements 
Heparinized venous blood was collected from additional 10 HDM-allergic individuals after 
informed consent was given. PBMCs were isolated by Ficoll (Amersham, GE Healthcare, 
Buckinghamshire, UK) density gradient centrifugation and T-cell proliferation assays were 
performed as described (17). 
Supernatants from parallel cultures of PBMCs which were stimulated identically as for the 
proliferation experiments were harvested at day 6. The levels of cytokines (IFN-gamma, GM-
CSF, IL-5, and IL-10, IL-13) released into the supernatants were measured using a Human 
Fluorokine MAP Base Kit (R&D Systems, Minneapolis, MN, USA) according to the 
manufacturer's protocol. 
 
Immunization of rabbits and mice 
Each of the Der p 2 peptides was coupled to KLH (MW 4.5 x 105 - 1.3 x 107 Daltons; Pierce, 
ThermoFisher Scientific, Waltham, MA, USA) and purified using a conjugation kit (Pierce, 
ThermoFisher Scientific) according to the manufacturer's protocol. 
Peptide-specific IgG antibodies were obtained by immunizing rabbits three times with each of 
the KLH conjugated peptides (200µg/injection) and, for control purposes, with recombinant 
Der p 2 protein (200µg/injection) using once Freund's complete and twice Freund's 
incomplete adjuvants (Charles River, Kisslegg, Germany). 
Eight-week-old female BALB/c mice were purchased from Charles River (Sulzfeld, 
Germany) and maintained according to the local animal care guidelines in the Animal Care 
Unit of the Institute of Pathophysiology of the Medical University of Vienna. Six groups 
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consisting of five mice each were monthly immunized subcutaneously into the neck with 5µg 
rDer p 2 or 5µg of each of the five KLH-conjugated Der p 2 peptides, absorbed to 200µl 
AluGel-S (SERVA Electrophoresis, Heidelberg, Germany). Blood samples were collected at 
the day before each immunization and stored at -20ºC. 
 
IgG antibody responses in mice and rabbits 
Der p 2-specific IgG antibody responses in mice were determined by ELISA as described (9). 
Specific IgG antibody responses in rabbits were measured in dot-blot assays. Aliquots of 2µl 
containing 0.2 g of rDer p 2, each of the five Der p 2 peptides and, for control purposes, 
BSA were dotted onto nitrocellulose membrane strips (Schleicher & Schuell). The strips were 
washed twice for 5 min and once for 30 min with buffer A. The nitrocellulose strips were then 
incubated with rabbit anti-sera raised against each of the five Der p 2 peptides (dilution 
1:10.000 in buffer A) or with the corresponding pre-immune sera (dilution 1:10.000 in buffer 
A) overnight at 4ºC. The nitrocellulose strips were washed with buffer A (2x 10 min, 1x 60 
min), bound rabbit IgG antibodies were detected with 125I-labeled donkey anti-rabbit IgG (GE 
Healthcare, Buckinghamshire, UK) (dilution 1:1000 in buffer A) and visualized by 
autoradiography. 
 
Inhibition of allergic patients’ IgE binding to rDer p 2 with peptide-specific IgG 
antibodies as determined by ELISA 
ELISA plates (Nunc, Roskilde, Denmark) were coated with rDer p 2 (0.5µg/well in PBS) 
overnight at 4°C. The plates were washed twice with PBST (PBS; 0.05% [v/v] Tween 20) and 
blocked in blocking buffer (PBST, 1% [w/v] BSA) for 3 h at room temperature. Then, rabbit 
anti-rDer p 2 antiserum, each of the rabbit anti-Der p 2 peptide antisera (anti-Peptide 1 - anti-
Peptide 5), mixtures of the rabbit antisera (anti-Peptide 1 – anti-Peptide 5 and anti-Peptide 2 + 
anti-Peptide 4 antiserum) and the corresponding pre-immune sera (1:100 dilution in PBST, 
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0.5% (w/v) BSA) were added to the plates and incubated overnight at 4°C. After washing, the 
plates were incubated with HDM-allergic patients' sera (1:10 dilution in PBST, 0.5% (w/v) 
BSA) overnight at 4°C. Bound human IgE antibodies were detected with HRP-coupled goat 
anti-human IgE antibodies (KPL, Gaithersburg, MD, USA) diluted 1:2500 in PBST, 0.5% 
(w/v) BSA as described (18). The percentage inhibition of IgE binding was calculated as 
follows: 100 - (ODs/ODp) x 100. ODs and ODp represent the extinctions after pre-incubation 
with the rabbit immune serum and pre-immune serum, respectively. 
 
CD203c expression on allergic patients´ basophils and inhibition of CD203c expression 
with specific IgG antibodies 
Heparinized blood samples from HDM-allergic patients were obtained after informed consent 
was given. Aliquots of 100µl blood were incubated with increasing concentrations of rDer p 2 
(0.066nM - 660nM), an equimolar mix of the five peptides, an equimolar mix of the five 
KLH-coupled peptides and, for control purposes, with a monoclonal anti-IgE antibody 
(1µg/ml) (Immunotech, Vaudreuil-Dorion, Quebec, Canada) or PBS for 15 min (37°C). 
CD203c expression was calculated from mean fluorescence intensities (MFIs) obtained with 
stimulated (MFIstim) and unstimulated (MFIcontrol) basophils and is expressed as 
stimulation index (SI) (SI = MFIstim:MFIcontrol) (19). 
In order to test whether peptide-specific IgG can inhibit allergen-induced up-regulation of 
CD203c expression, increasing concentrations of rDer p 2 (0.0005µg/ml - 0.5µg/ml) were 
pre-incubated with a 1:20 dilution of the rabbit anti-Der p 2 antiserum, the corresponding pre-
immune serum, or a mixture of the rabbit anti-peptide 2 and the anti-peptide 4 antisera at 
37°C for 60 minutes. Thereafter, blood samples from HDM-allergic patients (n=8) were 
incubated with these mixtures and CD203c expression and upregulation was assessed as 
described (19).  
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In vivo allergenicity of peptides, rat basophil leukaemia cell degranulation assay 
Serum samples were obtained from mice which had been immunized with aluminium 
hydroxide-adsorbed rDer p 2 (n=5) or with the KLH-coupled Der p 2 peptides (five mice per 
peptide) before or 16 weeks after immunization. Aliquots of 2 l serum from each mouse 
were then exposed to rat basophil leukemia cells (subline RBL-2H3) cultivated in 96-well 
tissue-culture plates (Nunc) (4 x 104 cells in 100µl) for 2h at 37°C. The releases of β-
hexosaminidase in the cultures were measured and are shown as mean percentages ±SD of 
total β-hexosaminidase releases (9). Unpaired Mann-Whitney-Tests were used to assess 
statistically significant differences between the mouse groups and SPSS statistical software 
system (SPSS Inc., Chicago, IL) was used for calculations. The reported p-values are the 
results of a two-sided test, corrected by Shaffer coefficient. A p-value smaller or equal to 0.05 
has been considered statistically significant. 
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RESULTS 
Characterisation of overlapping synthetic peptides covering the Der p 2 sequence 
We have synthesized five overlapping peptides of a length between 31 and 42 amino acids, 
which span the complete sequence of Der p 2 (Fig. 1A). When the peptides were 
superimposed to the 3D structure of Der p 2, the N-terminal peptide 1 and the C-terminal 
peptide 5 get close and define a surface patch on one side of the Der p 2 molecule (20) (Fig. 
1B, front). Figure 2 indicates the solvent-accessible surface of each amino acid of the Der p 2 
molecule and the contribution of the five peptides (peptide 1-5) to the Der p 2 molecule. The 
surface exposure of the individual Der p 2 derived peptides ranged from 19% (Peptide 5) to 
40% (Peptide 4) (Fig. 2B). The identity of each of the synthetic peptides was confirmed by 
MALDI-TOF analysis (data not shown). 
 
Synthetic Der p 2 peptides lack IgE reactivity and allergenic activity 
The IgE binding capacity of the five Der p 2 peptides was compared with that of the complete 
rDer p 2 allergen in non-denaturing dot blot RAST-based IgE binding assays using sera from 
28 HDM-allergic individuals (Fig. 3). Each of the patients showed IgE reactivity of varying 
intensity to rDer p 2 whereas none of the Der p 2 peptides showed any detectable IgE 
reactivity. When serum from a non-allergic person (NC) or buffer without serum (BC) were 
used, no reactivities to rDer p 2 or to Der p 2 peptides were found (Fig. 3, lanes NC, BC). 
None of the patients showed IgE reactivity to the control protein, BSA (Fig. 3). The correct 
binding of the peptides to the membrane was confirmed with peptide-specific rabbit 
antibodies (data not shown). 
The allergenic activity of Der p 2-derived peptides was compared with rDer p 2 wildtype by 
measuring CD203c expression on basophils from 8 additional HDM-allergic individuals 
which had been exposed to Der p 2 or the peptides (Fig. 4). rDer p 2 induced a strong up-
regulation of CD203c expression in all tested mite allergic individuals at concentrations 
 58 
CHAPTER 2 
between 0.66nM and 66nM, whereas no up-regulation was obtained with an equimolar 
mixture of the five peptides up to a concentration of 660nM (Fig. 4). Additionally, basophils 
were incubated with an equimolar mixture of the KLH-coupled peptides in order to test 
whether multiple coupling of the peptides to a carrier may influence allergenic activity. Also 
with KLH-coupled peptides no up-regulation of CD203c expression was obtained up to 
660nM (Fig. 4). Anti-human IgE antibodies induced up-regulation of CD203c expression on 
basophils from all patients, whereas no up-regulation was obtained with buffer alone (Co) 
(Fig. 4). 
 
Identification of Der p 2 peptides which induce no relevant lymphoproliferative 
responses in PBMCs from HDM-allergic patients 
Next we investigated the lymphoproliferative responses in PBMCs from 10 HDM-allergic 
patients to Der p 2, three earlier described recombinant hypoallergenic Der p 2 derivatives 
(rDer p 2 fragments 1, 2 and hybrid) (9) and the individual Der p 2 peptides (Fig. 5). PBMCs 
were stimulated with equimolar concentrations of Der p 2, the recombinant Der p 2 
derivatives or Der p 2 peptides. Der p 2 and Der p 2-derivatives induced T cell proliferation in 
PBMCs from all tested patients. Peptide 3 seemed to contain an important T cell epitope 
because it induced proliferative responses in 4 out of the 10 patients (patient 29, 33, 34 and 
36) and peptide 5 showed activity in 3 out of the 10 patients (patient 30, 33 and 34). The other 
peptides (Peptide 1, 2 and 4) induced only low or no T cell proliferation (Fig. 5). 
 
Der p 2 peptides induce less IFN-gamma than Der p 2 or Der p 2 derivatives in allergic 
patients’ PBMCs 
Table 1 shows the mean cytokine production in PBMCs from the same 10 patients after 
stimulation with Der p 2, recombinant Der p 2 derivatives or Der p 2 peptides. We found that 
Der p 2 and Der p 2 derivatives induced much higher levels of IFN-gamma in allergic patients 
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PBMC cultures than any of the Der p 2-derived peptides. We also observed a higher IL-10 
production in the Der p 2 and Der p 2-derivative-stimulated cultures compared to peptide-
stimulated cultures which may be due to the fact that IL-10 antagonizes in an autocrine 
manner T cell activation (21). The median levels of IL-5 and IL-13 in the Der p 2-, and the 
Der p 2- derivative-exposed cultures were higher than in the peptide-exposed culture but the 
differences were not statistically significant (Table 1). The production of GM-CSF was higher 
in Der p 2- and Der p 2 derivative cultures compared to peptide-containing cultures (Table 1). 
 
Immunization with KLH-coupled Der p 2 peptides induces Der p 2-specific IgG 
antibodies, which inhibit mite-allergic patients’ IgE binding to the Der p 2 allergen 
To determine whether Der p 2 peptides can induce an allergen-specific IgG response, mice 
and rabbits were immunized with rDer p 2 and KLH-coupled Der p 2 peptides. 
In a first set of experiments we studied the IgG response of rabbits, immunized with KLH-
coupled peptides, with dot-blotted Der p 2 and Der p 2 peptides (Fig. 6). Each of the five 
peptides induced Der p 2-specific IgG antibodies. The IgG response to Der p 2 was lower in 
the peptide 5-immunized rabbit than in the rabbits immunized with peptides 1-4. Certain 
peptides (e.g., peptides 1, 3 and 4) containing overlapping sequences with other peptides 
induced IgG antibodies which recognized also the adjacent peptides (Fig. 6). The pre-immune 
sera did not show any reactivity with Der p 2 or the Der p 2 peptides (Fig. 6). None of the 
rabbits showed IgG reactivity to the control protein, BSA (Fig. 6). 
We also immunized mice with Der p 2 or the KLH-coupled peptides using Aluminium 
hydroxide, an adjuvant commonly used for immunotherapy. Der p 2 specific IgG1 responses 
induced with rDer p 2 were higher and were detected earlier than IgG1 responses induced with 
the individual KLH-coupled peptides (Fig. 7). However, after week 8 robust Der p 2-specific 
IgG1 responses were induced by immunization with peptides 2 and 4 (Fig. 7). The other 
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peptides induced low (peptides 1, 3) or no (peptide 5) Der p 2-specific IgG1 responses at the 
given serum dilution (i.e., 1:1000). 
Next, we investigated whether IgG antibodies induced by immunization of rabbits with Der p 
2 peptides can inhibit mite-allergic patients’ IgE binding to Der p 2 in ELISA competition 
experiments. The percentage of inhibition of serum IgE binding to rDer p 2 wildtype by rabbit 
IgG antibodies is shown for 20 HDM-allergic patients (Table 2). Rabbit anti-rDer p 2 
antibodies inhibited patients’ IgE binding to rDer p 2 between 56.7 and 94.4% (mean 79.5%). 
Interestingly, the inhibitions obtained with rabbit anti-peptide 2 (mean 69.9%), anti-peptide 3 
(mean 77.7%) and anti-peptide 4 (mean 72.7%) antibodies were comparable to the inhibitions 
obtained with rabbit antibodies raised by immunization with the complete Der p 2 allergen. 
The inhibitions of patients’ IgE binding to Der p 2 with anti-peptide 1 antibodies were lower 
(i.e., 0-64.7%; mean 40.7%). Rabbit anti-peptide 5 antibodies showed no relevant inhibition 
of patients’ IgE binding to Der p 2 (i.e., 0-16.2%; mean 3.2%). A mixture of the anti-peptide 
2 and anti-peptide 4 antibodies inhibited IgE-binding between 56.2 and 92.9% (mean 79.3%) 
and thus equally well as a mixture of the five anti-peptide antibodies (i.e., 43.4-96.0%; mean 
77.8%) or anti-rDer p 2 antibodies (Table 2). 
 
Anti-Der p 2 peptide antibodies inhibit allergen-induced basophil activation 
IgG antibodies induced by immunization with Der p 2 peptides were tested for their ability to 
inhibit allergen-induced basophil activation. Increasing concentrations of Der p 2 were pre-
incubated with a mixture of rabbit anti-peptide 2 and anti-peptide 4 antibodies, anti-Der p 2 
antibodies or pre-immune IgG. Basophils from 8 HDM-allergic patients were then incubated 
with the Der p 2 - immune complexes and the up-regulation of CD203c expression was 
measured (Fig. 8). Pre-incubation of rDer p 2 with the mixture of the two anti-peptide 
antibodies strongly inhibited allergen-induced CD203c upregulation on basophils. The 
inhibitory effect achieved with this mixture was in certain patients (e.g., patients 32 and 35) 
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even stronger than the inhibition with antibodies obtained by immunization with the complete 
Der p 2 allergen. Overall a more than 10-fold reduction and in certain cases (e.g., patient 35) 
an up to 1000-fold reduction of sensitivity to Der p 2 could be achieved. 
 
Reduced in vivo allergenicity of Der p 2 peptides compared to Der p 2 
Der p 2 peptides were compared with rDer p 2 regarding their in vivo allergenicity. For this 
purpose mice were immunized with the KLH-coupled peptides or Der p 2 and the induction 
of Der p 2-specific reaginic IgE antibodies was then studied by loading RBL cells with the 
sera followed by allergen provocation (Fig. 9). Very low or no relevant release of β-
hexosaminidase was obtained when RBLs loaded with mouse anti-peptide IgE were exposed 
to Der p 2 (Peptide 1: mean 2.6%; Peptide 2: mean 4.9%; Peptide 3: mean 2.9%, Peptide 4: 
mean 11.5%; Peptide 5: mean 1.1%). By contrast, immunization with Der p 2 induced high 
levels of Der p 2-specific reaginic IgE yielding a mean Der p 2-specific degranulation of 
25.5% (Fig. 9).
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DISCUSSION 
Der p 2 is recognized by more than 90% of HDM-allergic patients and exhibits high in vivo 
allergenic activity (14, 22). Here we developed an approach for a Der p 2-based allergy 
vaccine which should eliminate IgE- and T cell-mediated side effects. Such as most other 
potent respiratory allergens, Der p 2 contains primarily conformational IgE epitopes and no 
relevant sequential IgE epitopes have been found so far (23, 24). We therefore synthesized 5 
overlapping Der p 2 peptides spanning the Der p 2 sequence to study if the disruption of the 
Der p 2 molecule into small fragments may abolish IgE reactivity and allergenic activity. A 
length of approximately 30 amino acids was chosen for the peptides because it has been 
shown for other respiratory allergens, that such peptides, when coupled to a carrier molecule, 
can induce robust IgG antibody responses against the intact wildtype allergen (15, 25, 26). 
When we tested the five peptides for IgE reactivity with sera from 28 HDM-allergic patients 
and basophil preparations from additional 8 patients, we found that none of the peptides 
showed any detectable IgE reactivity or allergenic activity. This result demonstrates that the 
majority of Der p 2 IgE epitopes belongs to the conformational type and provides a set of 
non-allergenic fragments for vaccine design. 
Several recombinant hypoallergenic Der p 2 derivatives with reduced IgE reactivity have been 
engineered earlier for SIT (3-9). These derivatives were made to reduce IgE-mediated side 
effects but preserved the majority of allergen-specific T cell epitopes. However, several 
clinical studies have shown that allergen-specific T cell epitopes induce IgE-independent, 
mainly late phase side effects (11-13, 27). We therefore compared the five Der p 2 peptides 
with Der p 2 and three hypoallergenic Der p 2 derivatives regarding their ability to induce 
specific T cell proliferation and cytokine responses in PBMC cultures from HDM-allergic 
patients. Der p 2 and the Der p 2 derivatives induced strong lymphoproliferative responses 
and the production of pro-inflammatory cytokines, among them IFN-gamma which has been 
shown to damage respiratory epithelial cells (28). Peptide 3, comprising aa 42-73 and peptide 
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5, comprising aa 98-129, also induced T cell proliferation, whereas peptides 1, 2 and 4 did not 
induce relevant proliferation or IFN-gamma production. Based on these results, peptides 1, 2 
and 4 should not induce IgE- and T cell-mediated side effects. Several immunotherapy studies 
performed with purified allergen molecules and hypoallergenic allergen derivatives have 
demonstrated that it is important to induce allergen-specific IgG antibodies which antagonize 
allergen recognition by IgE antibodies (10, 29-31). We therefore followed the principle of the 
hapten carrier concept described by Benaceraff and colleagues (32-34) and coupled the 
peptides to KLH for immunization experiments. Immunization of mice and rabbits showed 
that peptides 2, 3 and 4 induced robust Der p 2-specific IgG responses. These rabbit anti-
peptide 2, 3 and 4 antibodies inhibited allergic patients’ IgE binding to the allergen Der p 2 
almost as well as those induced with the complete allergen. Furthermore, anti-peptide 
antibodies also inhibited allergen-induced basophil activation and thus should suppress acute 
allergic inflammation. 
When we superimposed the area defined by peptides 2-4 onto the three-dimensional structure 
of Der p 2 (20), we found that it occupied one side of the Der p 2 molecule whereas peptide 5 
which failed to induce IgE-blocking responses and peptide 1 which induced low IgE-blocking 
responses defined an area on the other side of the Der p 2 structure. We thus assume that the 
majority of the Der p 2-specific IgE epitopes is located in the area defined by peptides 2-4. 
This assumption is supported by a careful in vitro mutagenesis study demonstrating that a Der 
p 2 mutant in which prolines 34, 95 and 99 have been exchanged retained structural fold but 
exhibited reduced IgE reactivity (6). Each of the three mutated amino acids is located in the 
area defined by us. 
Since peptide 3 induced T cell proliferation, we selected peptides 2 and 4 as minimal 
structural elements for the Der p 2 vaccine. Comparing a combination of anti-peptide 2 and 4 
antibodies with antibodies raised against the complete Der p 2 allergen we found that the 
combination of peptide 2 and 4-specific antibodies inhibited Der p 2-induced basophil 
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degranulation in allergic patients equally well as Der p 2-specific antibodies. Moreover, we 
found that immunization with peptide 2 and 4 did not induce allergic sensitization to Der p 2 
whereas immunization with Der p 2 induced allergenic IgE responses in mice. 
We thus have identified two Der p 2 peptides (peptide 2 and 4) as elements for a Der p 2 
allergy vaccine, which should allow avoiding IgE- and T cell-mediated side effects and 
should not induce allergic sensitization. The peptides may be conjugated to KLH or produced 
as fusion protein with other carrier molecules similar as described for a grass pollen peptide 
fused to the rhinovirus coat protein VP1 (26). 
The advantage of the carrier-bound peptides over the earlier described approach of using 
allergen derived T cell epitope-containing peptides (27) is that they induce robust allergen-
specific IgG antibodies and abolish or reduce T cell-mediated side effects originating from 
allergen-specific T-cells. The allergen-specific IgG antibodies should inhibit allergen-induced 
mast cell and basophil degranulation and thus immediate allergic symptoms (10, 30). 
Furthermore, allergen-specific IgG should reduce allergen-induced boosts of IgE production 
and thus downregulate allergen-specific IgE responses (10, 29, 35). Finally, allergen-specific 
IgG should inhibit IgE-facilitated allergen presentation and thus reduce T cell activation and 
release of pro-inflammatory cytokines (36-38). 
The peptide vaccine described by us thus should combine all the advantages of allergy 
vaccines based on wildtype allergens and recombinant hypoallergens (10, 29-31, 35). 
However, the carrier bound peptides should have advantages over previous approaches based 
on recombinant allergens, recombinant hypoallergens and T cell peptides (23), because they 
should not induce any IgE- or T cell-mediated side effects. Furthermore, the Der p 2-based 
peptide vaccine does not induce sensitization to the wildtype allergen and therefore may be 
also used for prophylactic vaccination. 
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Table 1: Expression of cytokines in PBMC cultures from 10 HDM-allergic patients after 
stimulation with medium, rDer p 2, Der p 2 derivatives or Der p 2 peptides. 
IFN-gamma GM-CSF IL-5 IL-10 IL-13
Medium 2.59 61.68 27.68 3.59 40.22
Der p 2 195.13 865.45 34.12 33.93 34.29
Der p 2 fragment 1 59.66 348.91 89.56 7.03 83.75
Der p 2 fragment 2 142.14 889.77 62.45 36.74 37.56
Der p 2 Hybrid 164.97 953.64 38.05 25.89 36.36
Peptide 1 2.59 56.12 11.52 3.59 38.94
Peptide 2 2.59 49.64 12.96 3.59 34.29
Peptide 3 2.59 78.80 18.43 3.59 39.37
Peptide 4 2.59 79.68 35.38 3.59 35.82
Peptide 5 2.59 62.97 21.00 3.59 40.65
Cytokine
 
The results are displayed as median value in pg/ml 
 
Table 2: Inhibition of allergic patients' IgE binding to Der p 2 with rabbit anti-Der p 2 
or anti-peptide antisera. 
Patient # Peptide 1 Peptide 2 Peptide 3 Peptide 4 Peptide 5 Peptide 1-5 Peptide 2,4 Der p 2
13 50.63 74.41 78.36 75.50 1.07 77.58 79.15 78.26
14 49.61 77.15 82.95 77.85 4.16 80.56 82.92 82.74
16 64.73 87.41 92.13 89.25 0.00 93.08 92.70 93.34
23 37.98 72.24 81.08 75.60 2.48 81.76 83.67 84.25
28 0.00 43.56 50.52 47.28 0.00 56.19 58.13 56.70
29 54.12 80.63 82.64 80.94 1.10 80.02 83.73 83.21
30 51.43 79.64 92.08 83.25 16.16 94.69 92.88 93.51
31 42.93 71.02 79.55 75.44 0.83 81.27 83.27 78.35
32 30.33 58.36 50.94 56.49 7.76 53.60 62.71 57.03
34 38.46 66.79 71.20 71.25 0.00 57.89 62.07 69.06
35 48.15 74.60 83.13 78.97 5.59 81.82 83.65 83.56
37 46.06 68.54 74.05 71.32 10.05 75.99 75.73 76.46
38 44.71 73.62 87.29 77.19 4.97 89.15 88.15 84.34
39 39.20 63.55 63.94 65.30 0.00 43.35 56.15 66.20
40 43.62 71.82 89.94 74.54 0.51 96.03 92.83 94.39
41 38.09 69.94 84.08 72.45 1.29 89.09 87.53 86.83
42 43.63 74.16 87.12 78.50 2.98 88.45 89.00 89.10
43 29.09 73.75 89.97 77.59 1.38 93.29 92.53 90.66
44 40.44 56.77 62.09 62.30 0.00 68.62 66.00 66.16
45 20.89 60.85 70.76 63.16 2.69 73.43 73.07 74.98
mean 40.71 69.94 77.69 72.71 3.15 77.79 79.29 79.46
Results are shown in % inhibition of IgE-binding 
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Figure legends 
 
Figure 1. (A) Amino acid sequence of Der p 2. Synthetic Der p 2-derived peptides 1-5 are 
indicated. B, Left images: Ribbon representations of the Der p 2 structure from the front and 
back. Alpha-helices and beta-sheets are indicated in red and yellow, respectively. Center and 
right images: Corresponding surface representations of the Der p 2 structure with peptides 1-5 
in different colours.  
 
Figure 2. Surface exposure of Der p 2 amino acids. A, The molecular surface exposure of 
each amino acid of Der p 2 (x-axis) displayed in Å2 (y-axis). B, The contribution of the 
peptides (peptide 1-5) to Der p 2 surface displayed in percentages (y-axis). 
 
Figure 3. IgE reactivity of rDer p 2 and Der p 2 peptides. Dot-blotted rDer p 2, Der p 2 
peptides and BSA were tested for IgE reactivity with sera from 28 HDM-allergic patients (1-
28), serum from a non-allergic individual (NC) and buffer without serum (BC). Bound IgE 
were detected with 125I labeled anti-human IgE antibodies and visualized by autoradiography. 
 
Figure 4. Allergenic activity of rDer p 2 and Der p 2 peptides determined by CD203c 
expression. Basophils from 8 HDM-allergic patients were incubated with various 
concentrations of rDer p 2, an equimolar mixture of the five peptides, an equimolar mixture of 
the five KLH-coupled peptides, anti-IgE and buffer (Co) (x-axes). Expression of CD203c was 
determined by FACS analysis and is displayed as stimulation index (SI) (y-axes). 
 
Figure 5. T cell proliferative responses of allergic patients to rDer p 2, rDer p 2 derivatives 
and Der p 2 peptides. PBMCs from 10 HDM-allergic patients (x-axis: 28-37) were stimulated 
with equimolar amounts of rDer p 2, rDer p 2 derivatives (Der p 2 fragment 1, 2 and Hybrid) 
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or Der p 2 peptides. T cell proliferation was measured by [3H]-thymidine uptake and is 
displayed as stimulation index (SI) (y-axis). 
 
Figure 6. Specificity of IgG antibodies induced by immunization of rabbits with Der p 2 
peptides. Sera obtained from 5 rabbits before (pre) or after (immune) immunization with 
KLH-coupled Der p 2 peptides (peptide 1-5) were tested for IgG reactivity to dot-blotted rDer 
p 2 or Der p 2 peptides. Bound IgG antibodies were detected with 125I-labeled donkey anti-
rabbit IgG antibodies. 
 
Figure 7. Der p 2-specific IgG1 responses of mice immunized with rDer p 2 or Der p 2 
peptides. Groups of five mice each were immunized with rDer p 2 or Der p 2 peptides in four 
weeks intervals. The optical densities (OD405nm) corresponding to the IgG1 antibody levels 
(y-axis) are displayed for groups of five mice as box plot diagram where 50% of the values 
are within the boxes and non-outliers between the bars. Lines within the boxes indicate the 
median values. Open circles and stars indicate outliers and extreme values of each mouse 
group. 
 
Figure 8. Inhibition of Der p 2-induced basophil activation by allergen-specific IgG 
antibodies. Various concentrations of rDer p 2 (0.0005-0.5µg/ml) were pre-incubated with 
rabbit anti-Der p 2 IgG, the corresponding pre-immune IgG or a  mixture of rabbit anti-
peptide 2 and anti-peptide 4 IgG. Basophils from 8 HDM-allergic patients were then 
incubated with the pre-incubated rDer p 2, anti-IgE or buffer (Co) (x-axes). Upregulation of 
CD203c expression on basophils determined by FACS analysis is displayed as stimulation 
index (SI) (y-axes). 
 
 73
CHAPTER 2 
Figure 9. Der p 2-specific basophil degranulation of RBL cells loaded with sera from mice 
immunized with rDer p 2 or Der p 2 peptides. RBL cells were loaded with serum IgE from 
mice obtained before (Pre-immuneserum) or after immunization (Immuneserum) with Der p 
2 or Der p 2 peptides 1-5. Der p 2 specific release of β-hexosaminidase is displayed as 
percentage of total release on the y-axis. Results are displayed as mean values  SD from 
each mouse group. Statistically significant differences are indicated. 
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Abstract 
Background: More than 50% of allergic patients suffer from house-dust mite (HDM) allergy. 
Group 1 and 2 allergens are the major HDM allergens. 
Objective: Production and preclinical characterization of a recombinant hypoallergenic 
combination vaccine for specific immunotherapy (SIT) of HDM allergy. 
Methods: Synthetic genes coding for two hybrid proteins consisting of reassembled Der p 1 
and Der p 2 fragments with (rDer p 2/1C) and without (rDer p 2/1S) cysteins were expressed 
in Escherichia coli and purified to homogeneity by affinity chromatography. Protein fold was 
determined by circular dichroism analysis, allergenic activity by testing IgE reactivity as well 
as basophil activation assays and presence of T cell epitopes by lymphoproliferation in 
allergic patients. Rabbits were immunized to study if the molecules induce allergen-specific 
IgG capable of inhibiting allergic patients’ IgE binding to the allergens. 
Results: rDer p 2/1C and rDer p 2/1S were expressed in large amounts in E. coli as soluble 
and folded proteins. Due to lack of disulfide bonds, rDer p 2/1S did not form aggregates and 
was obtained as monomeric protein, whereas rDer p 2/1C formed aggreates. Both 
hypoallergens lacked relevant IgE reactivity and allergenic activity but induced similar T cell 
proliferation as the wildtype allergens. Immunization with the hypoallergens (rDer p 
2/1S>rDer p 2/1C) induced IgG antibodies in rabbits that inhibited IgE reactivity of HDM-
allergic patients to Der p 1 and Der p 2. 
Conclusion: The preclinical characterization indicates that in particular rDer p 2/1S may be 
used as a safe hypoallergenic molecule for tolerance as well as vaccination approaches to treat 
HDM allergy. 
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Clinical implications: rDer p 2/1S is a recombinant hypoallergenic combination vaccine for 
safe specific immunotherapy of house dust mite allergy. 
 
Capsule Summary 
We present a hypoallergenic HDM allergy vaccine based on elements of Der p 1 and Der p 2. 
The vaccine induces IgG antibodies, which block patients’ IgE binding to Der p 1 and Der p 2 
and may thus be suitable for safe immunotherapy of HDM allergy. 
 
Abbreviations used 
SIT: specific immunotherapy 
HDM: house dust mite 
SI: stimulation index 
 
Key words: allergy, allergen, specific immunotherapy, recombinant hypoallergen, house dust 
mite allergy 
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INTRODUCTION 
Allergen-specific immunotherapy (SIT) represents the only allergen-specific and disease-
modifying approach with long-lasting effects for the treatment of allergic patients.1-5 
However, SIT may induce side-effects ranging from mild local to severe and life-threatening 
symptoms, such as anaphylactic shock.6-7 Severe side effects are frequently observed in house 
dust mite (HDM) allergic patients,8 who constitute more than 50% of allergic patients and 
often suffer from severe forms of respiratory allergy such as asthma. HDM allergic patients 
are also difficult to treat by SIT because they are on risk of being continuously exposed to 
allergens. Furthermore, the quality of natural HDM allergen extracts and vaccines based on 
these extracts is often poor. 
Although 23 different house dust mite allergens have been characterized, several studies 
indicate that group 1 and group 2 allergens represent the clinically most important HDM 
allergens. In fact, it has been shown that a combination of the Dermatophagoides 
pteronyssinus allergens, Der p 1 and Der p 2, allows diagnosis of more than 95% of HDM 
allergic patients.9-12 Therefore, Der p 1 and Der p 2 represent important components for a 
vaccine for HDM allergy. Several clinical studies indicate that SIT with recombinant 
hypoallergenic allergen derivatives which have been engineered to reduce their allergenic 
activity and thus therapy-induced side effects holds promise to improve SIT. Several 
promising hypoallergenic derivatives of group 2 mite allergens have already been 
developed,13-19 but so far no hypoallergenic derivatives for group 1 mite allergens have been 
reported which fulfil all the criteria of hypoallergens that have been successfully used in 
clinical trials. A recently reported rDer p 1 hypoallergen induced almost no allergen-specific 
IgG antibodies upon immunization of mice and a Der p 1 variant expressed in rice was tested 
only in mice but its allergenic activity and IgE reactivity in allergic patients has not been 
investigated.20-21 A hybrid molecule consisting of a truncated Der p 2 and Der p 1 was shown 
to exhibit reduced reactivity with patients IgE but it has not been unambiguously 
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demonstrated that this molecule was able to induce upon immunization of animals Der p 1-
specific IgG antibodies.22 
In this study we report the construction, purification, physicochemical, immunological and 
preclinical characterization of two recombinant hypoallergenic hybrid proteins, rDer p 2/1C 
and rDer p 2/1S consisting of reassembled elements of Der p 1 and Der p 2. In particular, rDer 
p 2/1S a hybrid molecule lacking all of the naturally occurring cysteine residues of Der p 1 
and Der p 2 could be expressed in large amounts in E. coli, lacked IgE reactivity and 
allergenic activity in HDM allergic patients and upon immunization of animals induced IgG 
antibodies which blocked allergic patients’ IgE binding to Der p 1 and Der p 2 fulfilling the 
preclinical requirements for a hypoallergenic vaccine for HDM allergy. 
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METHODS 
 
Human sera and HDM allergens 
Sera and blood samples were obtained from patients with HDM allergy and non-allergic 
individuals. The diagnosis of HDM allergy was based on a positive case history indicative of 
HDM allergy and positive SPT results and/or the demonstration of serum IgE antibodies to 
HDM extracts.9 Sera were analyzed in an anonymized manner with approval of the ethics 
committee of the Medical University of Vienna.  
Natural Der p 1 was isolated by affinity chromatography using the monoclonal antibody 4C1 
as described23 and rDer p 2 was expressed and purified as described.19 
 
Construction of Der p 2/1 mosaic proteins 
Two synthetic genes coding for the Der p 2/1 mosaic proteins displayed in Figure 1 were 
synthesized by ATG (ATG biosynthetics, Merzhausen, Germany) using codons optimized for 
the expression in E. coli. The two recombinant mosaic proteins consisted of three Der p 1 
fragments (1.1 aa1-84; 1.2 aa 85-143; 1.3 aa144-222) and two Der p 2 fragments (2.1 aa 1-53; 
2.2 aa 54-129) which were reassembled in the following order: 1.3, 2.2, 1.2, 2.1, 1.1. with 
(rDer p 2/1C) or without cysteines (rDer p 2/1S) and a C-terminal hexahistidines tag. The 
synthetic genes were cloned into the expression vector pET17b and the DNA sequences were 
determined by sequencing (ATG biosynthetics). 
 
Expression and purification of Der p 2/1 mosaic proteins 
Expression plasmids containing the Der p 2/1 constructs were transformed into E. coli strain 
BL21 (DE3) (Novagen, Merck, Darmstadt, Germany). Protein expression was performed in 
250ml liquid culture by induction with 0.5mM isopropyl-β-thiogalactopyranoside (IPTG) at 
an OD600 of 0.8 for 4h at 37°C and cells were harvested by centrifugation at 4000×g for 15 
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min at 4ºC. The bacterial pellets obtained from 250ml liquid culture were resuspended in 10 
ml 25mM imidazol, pH 7.4, 0.1% (v/v) Triton X-100. Cells were lysed by three 
freeze/thawing cycles (−70°C/+50°C), DNA was degraded by incubation with 1µg DNase I 
for 10 min at room temperature and cell debris were removed by centrifugation (10,000×g, 30 
min, 4°C). Der p 2/1C and Der p 2/1S mosaic proteins were found in the pellet in the 
inclusion body fractions, which were solubilised with 6M guanidine hydrochloride, 100mM 
NaH2PO4, 10mM Tris–Cl, pH 8 for 4h at room temperature. Insoluble debris were removed 
by centrifugation (10,000×g, 15 min, 4°C) and the two mosaic proteins were purified under 
denaturing conditions over Ni-NTA resin affinity columns (QIAGEN, Hilden, Germany). 
Fractions, containing recombinant proteins of more than 90% purity were dialysed against 
10mM NaH2PO4, pH 4.7 and the final protein concentrations were determined by BCA 
Protein Assay Kit (Novagen, Merck). 
 
SDS-PAGE under reducing and non-reducing conditions 
The purified Der p 2/1 mosaic proteins were mixed with SDS sample buffer with 5% vol/vol 
2-mercaptoethanol (reducing conditions) or without 2-mercaptoethanol (non-reducing 
conditions) and were separated by 14% SDS-PAGE.24 Proteins were visualized by Coomassie 
brilliant blue staining (Bio-Rad, Richmond, CA). 
 
Circular dichroism (CD) analysis 
The CD spectra of the proteins were measured on a JASCO (Tokyo, Japan) J-810 
spectropolarimeter. CD measurements were performed with nDer p 1, rDer p 1, rDer p 2, Der 
p 2/1C and with Der p 2/1S at protein concentrations of 0.1 mg/ml in 10mM NaH2PO4, pH 
4.7 using a rectangular quartz cuvette with a path length of 0.2 cm. Spectra were recorded 
from 190 to 260 nm with 0.5 nm resolution at a scan speed of 50 nm/min and resulted from 
averaging of three scans. The final spectra were corrected by subtracting the baseline spectra 
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obtained with the corresponding buffer (10mM NaH2PO4, pH 4.7) under identical conditions. 
Results are expressed as the mean residue ellipticity (Θ) at a given wavelength. 
 
IgE dot blot assays 
Aliquots of 2µl containing 0.1 mg/ml of nDer p 1, rDer p 2, the two mosaic proteins (Der p 
2/1C or Der p 2/1S) or, for control purposes, BSA were dotted onto nitrocellulose membrane 
strips (Schleicher & Schuell, Dassel, Germany). IgE reactivity of 21 mite allergic patients and 
two controls (NC: non-allergic person, BC: buffer control) to the dot-blotted proteins was 
determined as described.19 
 
Basophil activation assays 
Basophil activation was assessed in vitro by the determination of the up-regulation of CD203c 
expression. Heparinized blood samples from 8 mite allergic patients were collected after 
informed consent was given. Basophils were stimulated with various concentrations (0.04-
400nM) of nDer p 1, rDer p 2, Der p 2/1C or Der p 2/1S, and for control purposes, with a 
monoclonal anti-IgE antibody (1µg/ml) (Immunotech, Vaudreuil-Dorion, Quebec, Canada) or 
PBS for 15 min (37°C). Expression of CD203c was determined as described25. Allergen 
induced upregulation of CD203c was calculated from mean fluorescence intensities (MFI) 
obtained with stimulated (MFIstim) and unstimulated (MFIcontrol) cells and expressed as 
stimulation index (SI=MFIstim/MFIcontrol). 
 
Immunization of rabbits and determination of IgG responses 
Specific IgG antibodies were obtained by immunizing rabbits with each of the mosaic 
proteins, nDer p 1 or rDer p 2 (200µg/injection) using Freund's complete (CFA) and Freund's 
incomplete adjuvant (IFA) (Charles River, Kisslegg, Germany). 
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Rabbit IgG responses induced with the mosaic proteins were determined by non-denaturing 
dot blot assays. For this purpose, 0.2µg of nDer p 1, Der p 1 peptides (Der p 1 P1-P8), rDer p 
2, Der p 2 peptides (Der p 2 P1-P5), the two mosaic proteins and for control purposes BSA 
(0.1µg/µl) were dotted onto nitrocellulose strips (Schleicher & Schuell). The strips were then 
blocked with buffer A (40mM Na2HPO4, 0.6mM NaH2PO4, pH 7.5, 0.5% Tween 20, 0.5% 
[w/v] BSA, 0.05% [w/v] NaN3) and exposed to rabbit sera obtained by immunization with 
nDer p 1, rDer p 2, or the two mosaic proteins and to the corresponding preimmune sera 
(dilution 1:10000 in buffer A) overnight at 4ºC. Bound rabbit IgG antibodies were detected 
with 125I-labeled donkey anti-rabbit IgG (GE Healthcare, Buckinghamshire, UK) (dilution 
1:1000 in buffer A) and visualized by autoradiography (Kodak XOMAT film; Kodak, 
Heidelberg, Germany). 
 
ELISA for allergen-specific IgG reactivity and IgE inhibition assays 
Maxisorp ELISA plates (Nunc) were coated overnight at 4°C with nDer p 1 or rDer p 2 
(0.5µg/well in PBS), washed twice with PBST (PBS; 0.05% [v/v] Tween 20) and then 
blocked in blocking buffer (PBST, 1% [w/v] BSA) for 3 h at room temperature. Direct 
binding of rabbit antibodies to wildtype allergens was measured by incubation with serial 
tenfold dilutions of rabbit antibodies (1:100-1:10.000.000) made in PBST, 0.5% (w/v) BSA 
overnight at 4°C. After washing, bound rabbit IgG were detected with HRP-conjugated 
1:2000 diluted goat anti-rabbit Ig (Amersham, GE Healthcare) and measured as described.26 
IgE inhibition ELISA assays were performed as described.26 ELISA plates coated with nDer p 
1 or rDer p 2 were pre-incubated with rabbit anti-nDer p 1, rDer p 2, Der p 2/1C or rabbit 
anti-Der p 2/1S antisera (1:20), or the corresponding pre-immunesera (1:20) overnight at 4°C. 
After washing, the plates were incubated with mite allergic patients' sera (1:10). Bound 
human IgE antibodies were detected with HRP-coupled goat anti-human IgE antibodies 
(KPL, Gaithersburg, MD, USA) (1:2500). The percentage inhibition of IgE binding was 
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calculated as follows: 100 - (ODs/ODp) x 100. ODs and ODp represent the extinctions after 
pre-incubation with the rabbit immune serum and preimmune serum, respectively.26 When 
sera contained only low or no specific IgE reactivity to Der p 1 or Der p 2 (OD ≤ 0.3) the 
inhibition experiments could not be analyzed. 
 
T cell proliferation assays 
Heparinized venous blood samples were collected from HDM-allergic individuals (n=9) after 
informed consent was given. PBMCs were isolated by Ficoll (Amersham, GE Healthcare) 
density gradient centrifugation and stimulated with two different concentrations of nDer p 1, 
rDer p 2, rDer p 2/1C or rDer p 2/1S (0.2 or 0.05µM). Proliferation assays were performed as 
described and results are displayed as stimulation indices (SIs).27 
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RESULTS 
 
Purification and characterization of recombinant Der p 2/1 mosaic proteins 
With the aim to produce hypoallergenic combination vaccines for the major dust mite allergen 
Der p 1 and Der p 2, we have designed two mosaic proteins, each consisting of the entire 
sequence elements of Der p 1 and Der p 2 (Figure 1). Two previously defined hypoallergenic 
fragments of Der p 2 (Figure 1: 2.1 and 2.2)19 were shuffled with three Der p 1 fragments 
(Figure 1: 1.1, 1.2 and 1.3) in the form of two recombinant mosaic proteins, designated Der p 
2/1C and Der p 2/1S. Der p 2/1C contained the original aminoacid sequences of Der p 1 and 
Der p 2 including twelve cysteine-residues (dotted vertical lines), whereas in Der p 2/1S the 
cysteine-residues were replaced by serine-residues (Figure 1). The replacement of cysteine 
residues by serine residues was thought to reduce the potential aggregation behaviour of the 
Der p 2/1S protein. The selection of the three Der p 1 fragments was based on IgE and T cell 
epitope mapping studies (Chen et al., unpublished) suggesting that amino acids from 
fragments 1.1 and 1.3 contribute to conformational IgE epitopes on Der p 1 although the 
isolated fragments lacked IgE reactivity. In the mosaic proteins, fragment 1.3 was placed at 
the N-terminus, followed by the C-terminal Der p 2 fragment, 2.2, the original Der p 1 core 
fragment 1.2, the N-terminal Der p 2 fragment 2.1 and, at the C-terminus, the original N-
terminal Der p 1 fragment, 1.1. Through this arrangement it was thought to achieve a maximal 
displacement and reorientation of Der p 1 fragments 1.1 and 1.3. Both mosaic proteins were 
produced as C-terminally His-tagged proteins to facilitate purification.  
The two mosaic proteins were expressed in E. coli (Figure 2A, Lanes 1) and purified to 
homogeneity (Figure 2A, Lanes 2). SDS-PAGE analysis under reducing and non-reducing 
conditions demonstrated that under reducing conditions the two Der p 2/1 mosaic proteins 
migrated as monomeric proteins (Figure 2B, lanes r). However, under non-reducing 
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conditions Der p 2/1C occurred only in the form of high molecular weight aggregates, 
whereas Der p 2/1S appeared mainly as monomeric protein (Figure 2B, lanes nr). 
Next, we compared the fold of nDer p 1 and rDer p 2 with the mosaic proteins by circular 
dichroism analysis (Figure 3). nDer p 1 showed a high content of α-helical elements, which is 
characterized by a minimum at 208nm and at 222nm (Figure 3). The rDer p 2 CD spectrum 
exhibited a minimum at 215nm and a maximum at 197nm, which is typical for β-sheet 
proteins (Figure 3). The CD spectra of Der p 2/1C and Der p 2/1S were very similar 
exhibiting a broad minimum at 215nm and a maximum at 195nm, typical for proteins with a 
mixed α/β-fold (Figure 3). The CD spectrum of rDer p 1 resembled a denatured unfolded 
protein (data not shown).  
 
rDer p 2/1 mosaic proteins show almost no detectable IgE reactivity or allergenic 
activity 
The IgE binding capacities of the two Der p 2/1 mosaic proteins were compared with nDer p 
1 and rDer p 2 allergen in non-denaturing dot blot and RAST-based IgE binding assays using 
sera from 21 HDM-allergic individuals (Figure 4). Each of the allergic patients showed IgE 
reactivity to nDer p 1 and rDer p 2, whereas only three patients (i.e., patients 1, 8, and 18) 
showed very weak IgE reactivity to Der p 2/1C. A barely visible reaction to rDer p 2/1S was 
observed for two patients (i.e., patients 1 and 8) (Figure 4). None of the other patients showed 
any detectable IgE reactivity to Der p 2/1C and Der p 2/1S. When serum from a non-allergic 
person (NC) or buffer without serum (BC) was used, no reactivities to any of the dotted 
proteins were found (Figure 4, lanes NC, BC). None of the patients showed any IgE reactivity 
to the control protein, BSA (Figure 4). 
The allergenic activity of the two Der p 2/1 mosaic proteins was compared with nDer p 1 and 
rDer p 2 wildtype allergens by determining up-regulation of CD203c expression on basophils 
from HDM-allergic patients upon antigen exposure (Figure 5). Both wildtype allergens nDer 
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p 1 and rDer p 2 induced up-regulation of CD203c expression in the tested HDM-allergic 
patients. No up-regulations of CD203c expression were obtained with rDer p 2/1C or rDer p 
2/1S up to a concentration of 40nM. Only in three patients a weak up-regulation was observed 
at the highest concentration of 400nM (i.e., patients 5, 6 and 7) of rDer p 2/1C whereas rDer p 
2/1S did not induce basophil activation at any of the tested concentrations. Anti-human IgE 
antibodies were used as positive control and induced up-regulation of CD203c expression on 
basophils from all patients, whereas no up-regulation was obtained with buffer alone (data not 
shown). 
 
Recombinant Der p 2/1 mosaic proteins contain Der p 1 and Der p 2-specific T cell 
epitopes 
PBMC from 6 HDM allergic patients were stimulated with Der p 2/1 mosaic proteins, nDer p 
1 or rDer p 2. The stimulation indices in Table 1 show that both mosaic proteins induce 
lymphoproliferative responses comparable to those induced by the wildtype allergens at two 
antigen concentrations (i.e., 0.1 µM; 0.25 µM).  
 
Immunization of rabbits with the hypoallergenic Der p 2/1 mosaic proteins induced IgG 
antibodies which react with the wildtype allergens and inhibit allergic patients’ IgE 
binding to both allergens 
Both Der p 2/1 mosaic proteins induced Der p 1- and Der p 2-specific IgG antibodies whereas 
rabbit anti-Der p 1 and anti-Der p 2 antibodies reacted only with nDer p 1 and rDer p 2, 
respectively (Figure 6). None of the rabbit sera showed any reactivity to the control protein, 
BSA. Interestingly, rabbit anti-sera raised against the rDer p 2/1 mosaic proteins reacted with 
six of the eight Der p 1 peptides whereas the rabbit anti-nDer p 1 antiserum reacted only with 
two peptides (i.e., Der p 1 p4 and Der p 1 p6). Similar differences regarding the fine 
specificities of the antibodies were observed for the anti-rDer p 2 anti-serum which did not 
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react with peptide Der p 2 p2 whereas this peptide was strongly recognized by the anti-sera 
raised against the mosaic proteins (Figure 6). Thus, antibodies raised by immunization with 
mosaic antigens recognized more sequential epitopes than those obtained by immunization 
with the individual wildtype allergens.  
Despite the partial differences in the epitope specificities, the titers of anti-nDer p 1 and anti-
rDer p 2 antibodies were almost identical in the anti-sera raised against the recombinant 
mosaic proteins and in the anti-sera raised against nDer p 1 and rDer p 2 (Table 2). 
The inhibition of allergic patients’ IgE-binding to nDer p 1 or rDer p 2 by rabbit antibodies 
raised against the mosaic proteins is shown for 30 HDM-allergic patients in Table 3. Almost 
no inhibition of allergic patients IgE reactivity to Der p 1 was obtained with anti-rDer p 1 
antibodies, whereas antibodies raised by immunization with nDer p 1 strongly inhibited IgE 
binding to Der p 1 (i.e., 37.6-91.5%; mean 81.3%). The inhibition of IgE binding to nDer p 1 
achieved with rabbit anti-Der p 2/1S antibodies (i.e., 39.7-69.2%; mean 54.8%) was always 
better than that obtained with rabbit anti-Der p 2/1C (i.e., 30.3-68.7%; mean 45.3%). Anti-Der 
p 2 antibodies inhibited patients’ IgE binding to rDer p 2 between 67.2% and 94.4% (mean 
83.6%). The inhibition of allergic patients IgE binding to Der p 2 obtained with rabbit anti-
Der p 2/1C (i.e., 69.6-94.4%; mean 80.6%) and with rabbit anti-Der p 2/1S (i.e., 76.7-95.1%; 
mean 85.7%) antibodies was comparable with that of rabbit anti-Der p 2 antibodies (Table 3). 
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DISCUSSION 
Several clinical studies have demonstrated that SIT with recombinant birch and grass pollen 
allergens as well as with recombinant hypoallergenic allergen derivatives is clinically 
effective.5, 28 One major mechanism of vaccination treatment is the induction of allergen-
specific IgG antibodies, which compete with allergic patients’ IgE binding and hence inhibit 
IgE-mediated effector cell degranulation, T cell activation and boosts of IgE production.3, 5 
According to IgE reactivity data obtained for different populations and assessment of 
allergenic activity, group 1 and group 2 allergens from HDM must be considered as essential 
components of HDM allergy vaccines.9-10, 29 Recombinant group 2 allergens resembling 
structurally and immunologically the natural allergens as well as recombinant hypoallergenic 
derivatives of Der p 2 suitable for clinical trials have been produced.13, 17-19 However, fully 
IgE-reactive group 1 allergens have so far only been expressed in eukaryotic cells but not in 
E. coli.30-31 Hybrid molecules consisting of Der p 1 and Der p 2 thought for SIT either were 
instable or formed aggregates and therefore could not be used for clinical studies.32 A 
hypoallergenic Der p 1-Der p 2 derivative was reported but it has not been unambiguously 
shown that it induced IgG antibodies against Der p 1 and it is therefore not clear whether this 
vaccine will protect against sensitization to Der p 1.22 
The two recombinant hypoallergenic hybrid proteins described in our study address many of 
the hitherto unresolved problems regarding the construction of a hypoallergenic vaccine for 
HDM allergy. rDer p 2/1C and rDer p 2/1S combine all primary sequence elements of Der p 1 
and Der p 2 within one molecule, which can be expressed in large amount in E. coli and 
purified to homogeneity. Furthermore, both proteins show strongly reduced IgE reactivity and 
allergenic activity as demonstrated by IgE reactivity testing and in basophil activation studies 
in allergic patients. Since all primary sequence elements of Der p 1 and Der p 2 have been 
preserved and are combined in the proteins in the form of a mosaic, they resemble the T cell 
epitopes of the allergens, which may be required for SIT approaches aiming at the induction 
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of tolerance T cells. Finally, both proteins induce upon immunization IgG antibodies which 
recognize both allergens and inhibit allergic patients’ IgE binding to the wildtype allergens, a 
feature which has been shown to be important for clinical success in vaccination approaches 
based on recombinant allergens in clinical trials.5, 28 
Among the two candidate molecules, rDer p 2/1S appears to be the most promising candidate 
for clinical trials. Due to removal of all cysteines, rDer p 2/1S was unable to form aggregates 
via disulfide bonds and hence remained monomeric in solution which may facilitate its large 
scale production for clinical trials. Interestingly, both recombinant hypoallergens induced IgG 
antibodies against peptides against which no immune response could be obtained when rDer p 
2 and nDer p 1 wildtype allergens were used for immunization. The latter may be explained 
by the fact, that these domains became surface exposed and immunogenic in the reassembled 
mosaic proteins. Of note, rDer p 1 produced in E. coli showed no IgE reactivity but induced 
almost no IgG antibodies capable of recognizing natural Der p 1. It was therefore not 
surprising that IgG antibodies induced by immunization with E. coli-expressed rDer p 1 failed 
to inhibit allergic patients’ IgE binding to nDer p 1. By contrast, immunization with E. coli-
expressed rDer p 2/1S induced IgG antibodies which inhibited allergic patients’ IgE binding 
to Der p 2 as well as those induced by immunization with the allergenic rDer p 2 allergen and 
also strongly inhibited patients’ IgE binding to Der p 1. 
Another advantage of rDer p 2/1S was that it did not induce any relevant basophil activation 
in the tested patients and hence showed even a greater reduction of allergenic activity than 
rDer p 2/1C. 
In summary, rDer p 2/1S shows strongly reduced allergenic activity and IgE reactivity, 
contains all relevant T cell epitopes needed for tolerance induction strategies and induces 
robust protective allergen-specific IgG responses as needed for vaccine SIT approaches. It 
therefore may be considered as an extremely promising candidate molecule for clinical SIT 
trials in HDM allergic patients. 
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Table 1. Induction of lymphoproliferative responses with nDer p 1, rDer p 2 and rDer p 
mosaic proteins.  
nDer p 1 rDer p 2 rDer p 2/1C rDer p 2/1S nDer p 1 rDer p 2 rDer p 2/1C rDer p 2/1S
Patient 2 6.9 4.9 6.4 3.8 4.7 2.7 7.2 2.1
Patient 5 3.1 3.2 4.7 3.3 3.4 4.3 5.0 2.1
Patient 6 3.3 2.5 2.6 4.1 3.3 2.9 2.4 2.0
Patient 7 2.1 3.0 1.8 1.6 2.1 3.7 2.6 2.4
Patient 10 4.2 2.6 1.9 3.0 4.8 3.9 1.7 2.5
Patient 12 2.5 2.3 3.3 2.7 2.9 2.2 2.7 3.8
Patient 13 2.5 2.7 3.0 5.0 2.9 2.8 2.9 4.2
Patient 18 3.8 4.6 5.3 6.7 5.4 4.1 4.2 5.2
Patient 23 2.2 2.9 1.6 1.6 2.3 3.8 1.2 2.4
0.1µM 0.025µM
Allergen Allergen
PBMC from house dust mite allergic patients were stimulated with different concentrations of 
the proteins and stimulation indices (SIs) are displayed. 
 
 
Table 2. ELISA titrations of rabbit antisera. 
Dilution
rabbit anti-
nDer p 1
rabbit anti-
rDer p 2/1C
rabbit anti-
rDer p 2/1S
rabbit anti-
rDer p 2
rabbit anti-
rDer p 2/1C
rabbit anti-
rDer p 2/1S
1:100 1.156 1.188 1.024 1.268 1.307 1.081
1:1000 1.288 1.382 1.280 1.721 1.673 1.591
1:10000 1.261 1.023 1.169 1.168 1.054 1.263
1:100000 0.571 0.443 0.658 0.477 0.386 0.560
1:1000000 0.126 0.095 0.128 0.105 0.078 0.099
1:10000000 0.066 0.036 0.037 0.037 0.039 0.033
nDer p 1 rDer p 2
 
Mean OD values corresponding to bound IgG antibodies are displayed. 
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Table 3. Inhibition of allergic patients' IgE binding to nDer p 1 and rDer p 2 
with rabbit anti-nDer p 1, anti-rDer p 2 or anti-rDer p 2/1 antisera. 
nDer p 1 rDer p 1 Dp2/1C Dp2/1S rDer p 2 Dp2/1C Dp2/1S
Patient 1 88.9 0.0 54.8 60.2 91.3 88.7 92.0
Patient 2 91.5 0.0 37.5 48.6 83.3 83.0 87.8
Patient 3 90.6 0.0 61.7 61.9 94.4 94.5 95.1
Patient 4 66.8 0.0 41.8 55.8 71.5 72.6 78.4
Patient 5 n.a. n.a. n.a. n.a. 80.1 75.5 84.0
Patient 6 68.1 0.0 31.4 39.7 85.3 83.7 88.3
Patient 7 75.2 6.6 43.5 53.8 83.2 78.6 84.3
Patient 8 81.2 0.0 46.5 60.2 92.4 91.2 93.6
Patient 9 83.8 0.0 46.7 55.0 85.5 82.0 86.8
Patient 10 69.9 0.0 31.0 40.5 82.7 76.9 84.7
Patient 11 63.2 0.0 55.5 64.4 81.3 77.7 86.3
Patient 12 67.8 4.0 44.2 54.8 82.2 78.6 84.3
Patient 13 69.4 0.0 35.3 49.1 79.6 79.2 83.3
Patient 14 81.3 3.8 37.4 49.5 84.4 72.7 85.3
Patient 15 n.a. n.a. n.a. n.a. 78.7 76.9 83.3
Patient 17 n.a. n.a. n.a. n.a. 84.0 83.8 87.4
Patient 18 86.8 0.0 49.6 50.8 87.0 86.3 91.1
Patient 19 n.a. n.a. n.a. n.a. 71.7 72.0 76.7
Patient 20 37.6 0.2 30.3 69.2 77.3 72.2 83.4
Patient 21 79.4 0.0 47.3 64.4 84.6 81.5 86.1
Patient 22 n.a. n.a. n.a. n.a. 84.4 82.2 84.6
Patient 24 89.8 0.0 61.3 65.2 91.0 87.0 88.8
Patient 25 74.3 2.6 45.3 52.2 85.2 81.0 86.6
Patient 26 76.7 2.4 42.6 48.8 79.6 76.7 82.8
Patient 27 n.a. n.a. n.a. n.a. 84.3 81.2 87.0
Patient 28 n.a. n.a. n.a. n.a. 67.2 69.6 78.3
Patient 29 85.3 0.0 53.1 58.5 91.6 90.3 94.2
Patient 30 84.0 4.2 68.7 63.9 87.1 86.7 87.8
Patient 31 82.3 7.1 45.3 53.8 81.6 80.1 83.6
Patient 32 n.a. n.a. n.a. n.a. 78.1 78.7 82.5
mean 81.3 0.0 45.3 54.8 83.6 80.6 85.7
Inhibition to nDer p 1 Inhibition to rDer p 2
Rabbit anti- Rabbit anti-
 
Results are shown in % inhibition of IgE-binding 
n.a. could not be analyzed 
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Figure legends 
 
Figure 1. Construction of Der p 2/Der p 1 mosaic proteins. 
Three fragments of Der p 1 (1.1, 1.2 and 1.3) comprising amino acids (aa) 1-84, aa 85-143 
and aa 144-222  and two fragments of Der p 2 (2.1 and 2.2) comprising aa 1-53 and aa 54-129 
were reassembled in the order 1.3, 2.2, 1.2, 2.1, 1.1. Der p 2/1C contains the original aa 
sequence of Der p 1 and Der p 2 including the twelve cysteine-residues (dashed vertical lines) 
whereas in Der p 2/1S the cysteine-residues were exchanged to serine-residues. Both proteins 
contain a hexahistidine tag at the C-terminus. 
 
Figure 2. Expression and purification of recombinant Der p 2/Der p 1 mosaic proteins. 
Coomassie-stained SDS-PAGE containing protein extracts of BL21 (DE3) expressing Der p 
2/1C and Der p 2/1S (lanes 1), purified Der p 2/1C and Der p 2/1S (lanes 2) (A), purified Der 
p 2/1C and Der p 2/1S separated under reducing (lanes r) and non-reducing condition (lanes 
nr) (B), and molecular weight markers (lanes M). 
 
Figure 3. Far-ultraviolet CD spectra of nDer p 1, rDer p 2, rDer p 2/1C and rDer p 2/1S. 
Mean residue ellipticities (y-axis) at given wavelengths (x-axis) are shown for each protein. 
 
Figure 4. IgE reactivity of nDer p 1, rDer p 2 and rDer p 2/1 mosaic proteins. 
Dot-blotted nDer p 1, rDer p 2, the two Der p 2/1 mosaic proteins and BSA were tested for 
IgE reactivity with sera from 21 HDM-allergic patients (1-21), serum from a non-allergic 
individual (NC) and buffer without serum (BC). Bound IgE were detected with 125I labeled 
anti-human IgE antibodies and visualized by autoradiography. 
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Figure 5. Allergenic activity of nDer p 1, rDer p 2 and rDer p 2/1 mosaic proteins. 
Basophils from 8 mite allergic patients were stimulated with various concentrations of nDer p 
1, rDer p 2, rDer p 2/1C and rDer p2/1S (x-axes). Expression of CD203c was determined by 
FACS analysis and stimulation indices (SI) are shown (y-axes). 
 
Figure 6. Reactivity and epitope specificity of IgG antibodies induced by immunization of 
rabbits with nDer p 1, rDer p 2 and rDer p2/1 mosaic proteins. 
Sera obtained from rabbits before (pre) or after (immune) immunization with nDer p 1, rDer p 
2, rDer p 2/1C and rDer p 2/1S were tested for IgG reactivity to dot-blotted nDer p 1, rDer p 
2, rDer p 2/1 mosaic proteins and BSA or with synthetic Der p 1 and Der p 2-derived peptides 
(Der p 1 p1-p8; Der p 2 p1-p5). Bound IgG antibodies were detected with 125I-labeled donkey 
anti-rabbit IgG antibodies. 
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